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Abstract  
Modulation of co-inhibitory and co-stimulatory immune checkpoint molecules 
with antibody-based therapies has emerged as a promising anti-cancer 
strategy, however response rates to such agents are modest. The 
discrepancy in activity observed between mouse models and human cancers 
is rarely acknowledged, but deciphering this might provide valuable insights 
into underlying mechanisms of response and resistance. Through parallel 
analysis of mouse models and human cancers, this study demonstrates the 
importance of the local microenvironment in determining the activity of 
immune modulatory antibodies (mAb), providing novel insights into the 
mechanism of anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4, 
CD152) and anti-interleukin-2 receptor alpha chain (IL-2Rα, CD25) 
antibodies.  
 
A limitation of such approaches is the requirement for a pre-existing T cell 
infiltrate. In human tumours, paucity of immune infiltrate is well recognised, 
highlighting the need to identify relevant drivers of T cell infiltration. 
Complementary analysis of genomic and immunological landscapes in human 
tumours demonstrates that beyond total neoantigen burden, clonal 
architecture influences anti-tumour immunity, with prognostic implication and 
predictive value in the context of immune checkpoint modulation. Targeting 
clonal neoantigens, present on every tumour cell, might hold promise in 
overcoming the significant therapeutic challenge posed by tumour evolution 
and consequent intra-tumour heterogeneity. 
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1.  Introduction 
 
1.1 Mechanisms of therapeutic anti-CTLA-4 antibodies in cancer 
 
In contrast to monoclonal antibodies (mAbs) which specifically bind and 
destroy tumour cells, immune modulatory mAbs serve to engage or block the 
function of cell surface signalling molecules on host immune cells, influencing 
the direction and magnitude of the immune response (Yao et al., 2013). 
Immune modulatory mAbs targeting co-inhibitory and co-stimulatory immune 
checkpoint molecules were initially thought to act solely via regulation of 
effector T (Teff) cell responses. CTLA-4 was the first so-called ‘immune 
checkpoint’ molecule subject to therapeutic targeting in pre-clinical models 
and more recently clinical trials (Hodi et al., 2010; Robert et al., 2011). 
 
CTLA-4 and CD28 are homologous receptors expressed on both CD4+ and 
CD8+ T cells. They share a pair of ligands expressed on the surface of 
antigen-presenting cells (APCs) and mediate opposing functions in T cell 
activation. CD28 interacts with the CD80 dimer with relatively high affinity and 
the CD86 monomer with lower affinity, mediating T cell co-stimulation in the 
context of T cell receptor (TCR) signalling. CTLA-4 also interacts with both 
ligands, but does so with higher affinity and avidity than CD28 (Collins et al., 
2002; Schwartz et al., 2001; Stamper et al., 2001), serving to inhibit T cell 
responses. CTLA-4-CD80 binding represents the highest avidity interaction 
and CD28-CD86 the weakest, raising the possibility that CTLA-4 competes 
with CD28 for ligand binding and acts as an antagonist of CD28-mediated co-
stimulation (Thompson and Allison, 1997; Walker and Sansom, 2011). Such 
interaction occurs at the immune synapse between T cells and APCs, where 
CTLA-4 has been demonstrated to recruit CD80, limiting its interaction with 
CD28 (Pentcheva-Hoang et al., 2004; Yokosuka et al., 2010). 
 
Therapeutic anti-CTLA-4 mAbs were therefore initially proposed to exert anti-
tumour activity through competitive blockade of an inhibitory signal, promoting 
the expansion of Teff cells (Krummel and Allison, 1996; Leach et al., 1996). In 
support of this as a primary mechanism, in pre-clinical models, enhanced anti-
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tumour responses following CTLA-4 ‘blockade’ have been associated with 
CD8 T-cell-mediated autoimmunity, including depigmentation in melanoma 
models (van Elsas et al., 2001), prostatitis following vaccination against 
prostate cancer-specific antigens (Hurwitz et al., 2000) and the generation of 
anti-double-stranded DNA antibodies (Lute et al., 2005). However, CTLA-4 
was subsequently demonstrated to be constitutively expressed on regulatory 
T cells (Treg), raising the possibility of an additional impact of these mAbs on 
the Treg cell compartment (Read et al., 2000, 2006; Sakaguchi et al., 2001; 
Wing et al., 2008).   
 
Pre-clinical studies in mouse models of cancer demonstrated that targeting 
CTLA-4 on both Teff and Treg cell compartments was required for maximal 
anti-tumour activity, supporting the concept of an additional impact of anti-
CTLA-4 mAbs on Treg cells (Peggs et al., 2009). However, it was challenging 
to envisage a mechanism by which anti-CTLA-4 mAbs would differentially 
impact upon each compartment. Indeed, expansion of Teff and Treg cells in 
secondary lymphoid organs and blood of mice and humans had been 
demonstrated by multiple groups (Kavanagh et al., 2008; Quezada et al., 
2006; Schmidt et al., 2009), lending support to the existing concept that anti-
CTLA-4 mAbs act principally by promoting T cell expansion.  
 
A consistent observation associated with anti-CTLA-4-mediated tumour 
rejection had been an increase in the ratio of Teff to Treg cells within the 
tumour microenvironment (Chen et al., 2009; Curran and Allison, 2009; 
Kavanagh et al., 2008; Liakou et al., 2008; Quezada et al., 2006; Shrikant et 
al., 1999; Waitz et al., 2012). This was thought to occur secondary to 
preferential expansion of Teff over Treg, however it remained unclear why this 
was restricted to the tumour microenvironment and why a mAb 
simultaneously targeting two cellular populations with opposing activities 
favoured Teff cell function and promoted tumour rejection.   
 
More recent pre-clinical data in mouse models of cancer demonstrates that 
anti-CTLA-4 mAbs act to promote expansion of Teff and Treg cells in 
secondary lymphoid organs, whilst promoting Teff cell expansion and 
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concomitant depletion of Treg cells within the tumour (Bulliard et al., 2013; 
Selby et al., 2013; Simpson et al., 2013). Depletion of tumour-infiltrating Treg 
cells results in an increase in the ratio of Teff to Treg cells and tumour 
rejection (Figure 2).  
 
 
Figure 1: Activity of anti-murine CTLA-4 antibodies depends upon local 
microenvironment 
Reproduced with permission from (Furness et al., 2014). In lymph node (LN) anti-CTLA-4 
antibodies expand both Teff and Treg cell populations. In contrast, the tumour 
microenvironment is enriched with FcγR-expressing cell subsets and CTLA-4 upregulated on 
Treg relative to Teff cells. As a consequence, preferential elimination of Treg cells occurs via 
ADCC. This activity is restricted to the tumour microenvironment and mediates a shift in the 
intra-tumoural CD8/Treg cell ratio resulting in tumour rejection.  
 
Depletion of tumour-infiltrating CTLA-4+ Treg cells occurs via antibody-
dependent cell-mediated cytotoxicity/phagocytosis (ADCC/P), mediated by 
tumour-infiltrating CD11b+ macrophages expressing the activatory fragment 
crystallisable gamma receptor IV (FcγRIV). Macrophages appeared enriched 
in tumour relative to lymph node (>50-fold), where they were observed 
express higher relative levels of FcγRIV, explaining the paradoxical impact of 
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anti-CTLA-4 mAbs on Teff and Treg cell accumulation in secondary lymphoid 
organs versus the tumour (Bulliard et al., 2013; Simpson et al., 2013). 
Preferential depletion of Treg over Teff cells results from higher relative 
expression (based on mean fluorescence intensity (MFI)) of CTLA-4 on Treg 
cells.  In keeping with this, a small population of Teff cells expressing high 
levels of CTLA-4 was also eliminated, highlighting the relevance of density of 
target molecule expression in the context of mAbs with depleting activity 
(Simpson et al., 2013).  
 
Taken together, these data demonstrated a previously unappreciated dual 
activity of murine anti-CTLA-4 mAbs. Without blocking activity, Teff cells 
would not expand, infiltrate and accumulate; without depleting activity, Treg 
cells would not be eliminated and the intra-tumoural balance would continue 
to favour tumour progression. 
 
1.2 A common mechanism for anti-GITR and anti-OX40 antibodies  
A similar requirement for activating FcγRs in the activity of anti-glucocorticoid-
induced tumour necrosis factor (TNF)-related protein (GITR) and anti-OX40 
antibodies was recently demonstrated (Bulliard et al., 2013, 2014). Surface 
expression of GITR and OX40 appeared significantly higher on tumour-
infiltrating Treg cells relative to Teff cells. Myeloid cells expressing activating 
FcγRs were enriched in the tumour microenvironment and under-represented 
in tumour-draining lymph nodes.  Similar to observations with anti-murine 
CTLA-4 mAbs, following the administration of therapeutic mAbs, rapid 
depletion of tumour-infiltrating Treg cells was observed, mediating a shift in 
the intra-tumoural Teff/Treg cell ratio and tumour rejection, supporting a 
common mechanism shared between mAbs targeting B7 and TNFR 
molecules. 
 
1.3 Fc gamma receptors as regulators of immune response 
The capacity of an individual mAb to mediate ADCC/P depends on the 
expression profile of the target molecule, antibody isotype and the local 
abundance of FcγR-expressing innate effector cells (Bulliard et al., 2013, 
2014; Furness et al., 2014; Simpson et al., 2013). Fcγ
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expressed on cells of haematopoetic lineage including B cells, dendritic cells, 
macrophages, mast cells, natural killer (NK) cells and neutrophils 
(Nimmerjahn and Ravetch, 2007). They are divided functionally into two 
classes: activating and inhibitory receptors. Activating receptors comprise 
human (h) FcγRI, FcγRIIa, FcγRIIIa/b and mouse (m) orthologues FcγRIa, 
FcγRIII and FcγRIV (Figure 1). 
 
 
 
Figure 2: Structure and function of human and mouse Fc gamma receptors. 
Reproduced with permission from (Schwab and Nimmerjahn, 2013). Schematic 
representation of Fc gamma receptors at the cell membrane and their association with the 
FcRγ-chain dimer in mice (upper panel) and humans (lower panel). Green boxes represent 
immunoreceptor tyrosine-based activation motifs (ITAMs) and red boxes immunoreceptor 
tyrosine-based inhibitory motifs (ITIMs). Predicted binding of IgG subclasses is displayed 
between upper and lower panels and functional outcome at bottom of figure. 
 
Activating FcγRs possess an immunoreceptor tyrosine-based activation motif 
(ITAM) within their intra-cytoplasmic domain, or, in the case of hFcγRI and 
IIIa, associate with the ITAM-containing signalling subunit Fc receptor (FcR) 
common gamma chain (Guilliams et al., 2014). FcγRIIb is the only inhibitory 
receptor in mice and humans, consisting of an immunoreceptor tyrosine-
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based inhibition motif  (ITIM) in its intra-cytoplasmic domain (Ravetch and 
Lanier, 2000). A key feature of the FcγR system is co-expression of activating 
and inhibitory receptors on the same cell. This serves to set thresholds for 
activation, with potentially important implications for mAb selection and/or 
design. The exception to this is B cells, which exclusively express inhibitory 
FcγRIIb, and human natural killer (NK) cells, which express activating 
FcγRIIIa alone. 
 
The molecular mechanisms by which clustering of FcγRs trigger or suppress 
cell activation are crucial in mediating appropriate responses to IgG-
complexed antigens. Clustering of activating FcγRs leads to activation of 
intracellular SRC-family protein kinases (including SRC, FYN, FGR, HCK and 
LYN) and phosphorylation of tyrosine residues in the ITAM. The 
phosphorylated ITAM then serves as a docking site for the SRC-homology 2 
(SH2) domain of the cytosolic protein SYK (Ghazizadeh et al., 1994; Wang et 
al., 1994). Activating signalling through ITAM-containing FcγRs leads to an 
oxidative burst, cytokine release and phagocytosis by macrophages, ADCC 
by NK cells or degranulation of mast cells (Takai, 2002).  
 
The activation pathway can be inhibited by co-aggregation of FcγRIIb, which 
acts physiologically as a negative regulator of immune complex-triggered 
activation. Its function is best described within B cells, in which the initial event 
in inhibitory signalling is phosphorylation by the SRC-family kinase LYN of the 
ITIM tyrosine found in the FcγRIIb cytoplasmic tail (Muta et al., 1994). This 
results in recruitment of SH2-domain-containing phosphatases, principally the 
SH2-domain-containing protein tyrosine phosphatase 1 (SHP1), SHP2 and 
SH2-domain-containing inositol polyphosphate ‘5 phosphatase (SHIP) 
(D’Ambrosio et al., 1995; Damen et al., 1996; Muta et al., 1994; Ono et al., 
1996). SHIP is the primary effector of FcγRIIb-mediated inhibition, acting to 
dephosphorylate phosphoinositides and inositol polyphosphates. Its main in 
vivo substrate is phosphatidylinositol-3,4,5-triphosphate (PtdIns(3,4,5)P3) 
which is formed by the action of phosphatidylinositol 3-kinase (PI3K). 
Thereafter, the proposed signalling cascade of inhibition occurs via three 
distinct, but interacting pathways: (i) SHIP-mediated hydrolysis of 
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PtdIns(3,4,5)P3, which leads to impaired membrane translocation of signal-
transducing molecules (Bolland et al., 1998; Fluckiger et al., 1998; 
Scharenberg et al., 1998) (ii) suppression of the activation of mitogen-
activated protein (MAP) kinases and recruitment of the anti-apoptotic kinase 
AKT (Liu et al., 1998) and (iii) inhibition of RAS activation through SHIP 
binding to FcγRIIb (Tamir et al., 2000; Tridandapani et al., 1997a, 1997b). 
 
The fate of immune complexes (ICs) will therefore vary, depending on the 
encountered cell subset and FcγR expression profile. Under steady state 
conditions, the inhibitory receptor dominates, secondary either to higher 
expression, or a greater affinity for abundant antibody isotypes (Kalergis and 
Ravetch, 2002).  In health, this is critical in order to avoid non-specific immune 
activation, however, in the context of disease, this balance may impact 
significantly upon outcome.  
 
1.4 Fc gamma receptors and antibody isotype  
The efficacy of mAb-mediated ADCC depends upon the relative affinity of 
individual immunoglobulin G (IgG) subclasses for activating and inhibitory 
FcγRs. Recent studies have determined the affinity of monomeric antibody 
isotypes for their respective activating and inhibitory FcγR pairs, allowing 
generation of an activating to inhibitory FcγR binding ratio (A:I) (Bruhns et al., 
2009; Nimmerjahn et al., 2005).  Assigned A:I ratios for individual antibody 
isotypes correlate with therapeutic activity in-vivo.  In mice, mIgG1 antibodies 
have an A:I ratio of less than 1; the depleting activity of this isotype is 
therefore strongly governed by the inhibitory FcγRIIb.  In contrast, mIgG2a 
and mIgG2b have A:I ratios of up to 70, and are therefore less regulated by 
FcγRIIb. It follows that mIgG2a and mIgG2b isotypes are recognised to be 
more efficient in target cell depletion than mIgG1 and mIgG3 (Hamaguchi et 
al., 2006) and that in models of tumour cell killing and platelet depletion by 
IgG Fc variants, deletion of FcγRIIb was found to impact most strongly on 
mIgG1 activity (Nimmerjahn and Ravetch, 2005). In the humans, the affinity of 
IgG subclasses differs, such that hIgG1 and hIgG3 have a higher affinity for 
both activating and inhibitory FcγRs than their hIgG2 and hIgG4 counterparts, 
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with hIgG1 typically selected for clinical reagents where ADCC activity is 
desirable (Bruhns et al., 2009).  
1.5 Fc gamma receptor polymorphisms and response to monoclonal 
antibodies in cancer 
Monoclonal antibodies have been used extensively against cancer. In this 
setting they act to block the interaction of soluble ligands with target 
receptors, bind to cell surface antigens on tumour cells, modulating signal 
transduction (Li et al., 2005), or, deplete/phagocytose antigen-expressing 
target cells by ADCC or ADCP (Johnson and Glennie, 2003). In this regard 
there is strong evidence from pre-clinical models that ADCC and ADCP 
effector function is critical to the therapeutic activity of hIgG1 mAbs targeting 
CD20 (de Haij et al., 2010), human epidermal growth factor receptor 2 (HER-
2) (Barok et al., 2007) (Clynes et al., 2000) (Musolino et al., 2008), epidermal 
growth factor receptor 2 (EGFR) (Hara et al., 2008), fibroblast growth factor 
receptor 3 (Li et al., 2005) and CD52 (Golay et al., 2006).  
Demonstrating this in vivo has proved more challenging, perhaps the 
strongest evidence for a role of FcγR-mediated effector function in antibody-
based cancer therapies derives from clinical studies demonstrating an 
association between clinical responses and specific alloforms of activating 
hFcγRs (Cartron et al., 2002; Musolino et al., 2008; Weng and Levy, 2003; 
Zhang et al., 2007).  
A non-synonymous polymorphism (519G>A, rs1801274) in exon 4, encoding 
the membrane proximal Ig-like domain of FCGR2A, leads to an arginine (R) to 
histidine (H) change at position 131, altering receptor affinity for ligand. In 
contrast to the R131 allele, the FcRIIa-H131 allele readily binds to human 
IgG2 (Parren et al., 1992; Salmon et al., 1992). Given that hFcγRIIa is the 
most broadly expressed hFcγR across a range of cell subsets, this has 
significant implications for human disease beyond the setting of malignancy 
(Li et al., 2014). In the second extracellular domain of FCGR3A, a point 
substitution of T to G at nucleotide 559 (rs396991) changes the phenylalanine 
(F) at amino acid position 158 to valine (V). The FcγRIIIa-158V allele displays 
higher affinity for IgG1 and IgG3 relative to the 158F allele and is also capable 
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of binding IgG4. Similar to the FcRIIa-H131, beyond the context of human 
cancer, the FcγRIIIa-158V polymorphism has been associated with 
pathogenesis, including a predisposition to the development of autoimmune 
disease (Koene et al., 1997; Wu et al., 1997).  
However, whilst multiple clinical studies have identified a relationship between 
hFcγR polymorphism status and response to cancer cell targeting mAbs such 
as Rituximab (reviewed in Mellor et al., 2013), there has been no formal 
assessment of the impact of such polymorphisms on response to anti-CTLA-4 
or other immune modulatory mAbs. Where ADCC may be relevant to the 
activity of immune modulatory mAbs, both antibody isotype and hFcγR 
polymorphism status are potentially highly relevant. This is further apparent 
when considering the current pipeline of U.S. Food and Drug Association-
approved immuno-oncology (I-O) mAbs (Table 1).  
Target! Company! Drug! First!
approved!
Approved 
indications!
Isotype! Predicted  
ADCC activity!
CTLA-4! BMS! Ipilimumab! 2011! Melanoma! IgG1! Yes!
PD-1! Merck! Pembrolizumab! 2014! Melanoma, 
NSCLC, HNK 
Bladder, HD!
IgG4! No!
PD-1! BMS! Nivolumab! 2014! Melanoma, 
NSCLC, RCC, 
bladder, HD!
IgG4! No!
PD-L1! Roche! Atezolizumab! 2016! Bladder! IgG1 
N298A! No!
PD-L1! Merck! Avelumab! 2017! Merkel cell ! IgG1! Yes!
PD-L1! AZ! Durvalumab! Submitted!
2017! Bladder, NSCLC! IgG1*! No!  
Table 1: FDA-approved immune modulatory antibodies 
AZ, AstraZeneca, BMS, Bristol-Myers Squibb, HD, Hodgkin disease, HNK, head and neck 
carcinoma, NSCLC, non-small cell lung cancer and RCC, renal cell carcinoma. 
*glycoengineered to abrogate Fc function. 
Three anti-PD-L1 mAbs are FDA-approved, of these, only Avelumab has 
predicted ADCC activity. In pre-clinical models, anti-PD-L1 mAbs with 
capacity for ADCC displayed augmented anti-tumour activity relative to those 
without (Dahan et al., 2015). Although these mAbs will almost certainly never 
undergo head-to-head evaluation in clinical trials, it is paramount moving 
forward that such pre-clinical studies inform the design of the next generation 
of therapeutic mAbs for clinical application.  
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1.6 Barriers to clinical translation  
Ipilimumab, a human IgG1 mAb directed against CTLA-4, mediates durable 
remissions in patients with advanced melanoma, although such responses 
are limited to a small subset (Hodi et al., 2010; Robert et al., 2011; 
Schadendorf et al., 2015). Despite its potentially depleting isotype, the 
contribution of ADCC and role of FcγRs in the activity of ipilimumab in vivo 
remains controversial. Two recent clinical studies have identified a reduction 
in tumour-infiltrating Treg cells post ipilimumab therapy (Romano et al., 2015; 
Tarhini et al., 2014). Moreover, in vitro studies demonstrate that ipilimumab 
depletes CTLA-4-expressing Treg cells in the presence of FcγR-expressing 
monocytes and NK cells, consistent with predicted binding affinity for 
activatory FcγRs (Jie et al., 2015; Romano et al., 2015). A second anti-CTLA-
4 mAb, tremelimumab, has also displayed activity in early phase studies 
(Comin-Anduix et al., 2016). In contrast to ipilimumab, a human IgG2 isotype 
was selected during pre-clinical design to minimize potential ADCC/ADCP 
activity (Hanson et al., 2004), thus arguing against a role for Treg cell 
depletion in the activity of anti-CTLA-4 mAbs in humans.   
Deciphering the contribution of Fc-FcγR interaction to the activity of immune 
modulatory antibodies is likely to significantly inform the optimal design of the 
next generation of therapeutics. The biological activity of specific IgG Fc 
subclasses depends upon their relative affinity for activatory and inhibitory 
FcγRs (Bruhns et al., 2009; Nimmerjahn and Ravetch, 2005). Mutagenesis 
and glycoform engineering of mAbs has been demonstrated to modulate the 
affinity of Fc-FcγR interaction, with impact upon cytotoxicity in cell-based 
assays (Duncan et al., 1988; Redpath et al., 1998; Sarmay et al., 1992; 
Shields et al., 2001, 2002). Such findings have informed the development of 
mAbs engineered to display superior activatory to inhibitory FcγR binding 
profiles and improved ADCC activity (Lazar et al., 2006).  
In this context, efficacy studies in mouse models represent an important step 
in the pre-clinical development of antibody-based therapies. However, reliable 
translation of such findings across species is often problematic owing to 
variation in FcγR subtypes, their distribution and the affinity of individual IgG 
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subclasses in each species. In addition, the previously described 
polymorphisms in human FcγRs may further influence the binding and 
biological effects of different IgG subtypes (Koene et al., 1997; Warmerdam et 
al., 1991; Wu et al., 1997).  
The first objective of this study was to bridge this translational void in attempt 
to better inform the design of the next generation of immune modulatory mAbs 
optimised appropriately for agonistic, blocking or depleting activity according 
to the expression profile of relevant target molecules, desired effector function 
and features of the local microenvironment. 
1.7 Towards the identification of selective targets for T cell 
modulation 
Beyond CTLA-4 and PD-1, monoclonal antibodies targeting further co-
inhibitory and co-stimulatory immune checkpoint molecules are currently 
under evaluation in clinical trials (Furness et al., 2014). Increasingly, 
combination strategies are employed, in this setting toxicity is common, grade 
III/IV adverse events were observed in 55% of study participants with 
advanced melanoma treated combination anti-CTLA-4/PD-1 antibodies within 
a recent phase III study (Larkin et al., 2015).  
 
Characterisation of the immune landscape in sites commonly associated with 
immune-related adverse events (IRAE) including skin, colon and pituitary is 
paramount in order to inform the design of mAbs displaying optimal activity 
but with greater restriction to the tumour microenvironment. A recent 
translational study demonstrated ‘ectopic’ expression of CTLA-4 on human 
pituitary endocrine cells at both ribonucleic acid (RNA) and protein levels, 
providing insights into the possible aetiology of ipilimumab-mediated 
hypophysitis (Iwama et al., 2014).  
 
Whilst many of these adverse events appear to be reversible with early 
recognition and prompt administration of high dose steroid therapy, 
devastating outcomes have been reported in the literature (Johnson et al., 
2016).  This has prompted modification of dosage and scheduling within 
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clinical trials (Long et al., 2017), however this is no substitute for translational 
studies dissecting the mechanisms underlying such off target toxicity. Another 
method by which toxicity might also be reduced is through the identification 
and in vivo evaluation of targets with a more restricted expression profile 
(relative to CTLA-4 or PD-1), allowing more selective targeting of T cell 
populations. 
 
1.8  CD25 as a selective target for regulatory T cells  
 
CD25, the interleukin-2 high affinity receptor alpha chain (IL-2Rα), was first 
identified by Sakaguchi and colleagues (Sakaguchi et al., 1995) and used as 
a surface marker for the identification and isolation of Treg cells prior to the 
discovery of their master regulator, transcription factor forkhead box P3 
(FoxP3) (Fontenot et al., 2005).  
 
CD4+FoxP3+CD25+ regulatory T cells play a key role in the maintenance of 
peripheral self-tolerance. Characterisation of the mechanisms underlying this 
remains an area of scientific enquiry, however they act, at least in part, to 
regulate CD4+ and CD8+ T cell activity in a cell extrinsic manner, and their 
depletion leads to enhanced T cell responses to pathogens (Mendez et al., 
2004), self-antigens (Kim et al., 2007) and tumours (Onizuka et al., 1999; Turk 
et al., 2004). Sakaguchi and colleagues demonstrated that Treg cells with 
strong suppressive capacity are defined by the expression of CD25 
(Sakaguchi et al., 1995). Elimination of CD25+ Treg cells results in the 
development of autoimmunity in rodents, whilst adoptive transfer of Treg cells 
prevents the onset of autoimmune diseases (Salomon et al., 2000; Stephens 
and Mason, 2000; Suri-Payer et al., 1998). It follows that CD25 has been 
extensively studied as a target for therapeutic Treg cell depletion. 
 
1.9 Therapeutic targeting of CD25 in pre-clinical and clinical studies 
Pre-clinical studies in mouse models of cancer have principally evaluated the 
anti-CD25 antibody clone PC61 (rat IgG1, λ). This has been demonstrated to 
partially deplete Treg cells in the blood and peripheral lymphoid organs of 
mice via murine FcγRIII (Setiady et al., 2010). Consistently within these 
studies, CD25-directed Treg cell depletion has been observed to synergise 
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with a variety of immunotherapeutic approaches, although this only occurs 
when it is administered either prior to or soon after tumour challenge. In this 
context, depletion of circulating or LN-resident Treg cells with anti-CD25 mAb 
appears to augment or induce anti-tumour immunity. However this approach 
lacks translational value, reflected in the observation that the use of anti-CD25 
mAbs as a therapeutic intervention against established tumours has 
consistently failed to delay tumour growth and/or prolong survival (Golgher et 
al., 2002; Jones et al., 2002; Onizuka et al., 1999; Shimizu et al., 1999).  
 
Quezada and colleagues sought to shed light on this, evaluating the impact of 
therapeutic CD25 depletion on established tumours, with use of an anti-CD25 
mAb (PC61 clone) or administration of diphtheria toxin (DT) in FoxP3-DTR 
transgenic mice. It had previously been demonstrated that the anti-tumour 
activity of GVAX (a whole tumour cell vaccine expressing human GM-CSF) in 
combination with anti-CTLA-4 mAbs (9H10 clone) varied depending on timing 
of administration, such that efficacy was reduced when used more than four 
days after implantation of the B16/BL6 cell line (van Elsas et al., 1999). They 
hypothesised that Treg cells might be contributing to the observed lack of 
activity and therefore CD25-directed depletion of Treg cells might effectively 
synergise with GVAX/anti-CTLA-4 (anti-CTLA-4 mAbs had not been 
demonstrated to deplete Treg cells at this time).  
 
Combination vaccination therapy (GVAX/anti-CTLA-4) was delayed until 8 
days after tumour implantation, a time point at which GVAX/anti-CTLA-4 is 
incapable of rejecting established tumours. ‘Prophylactic’ CD25 depletion 
(administered on day -4) and GVAX/anti-CTLA-4 synergised to reject 
established tumours, however therapeutic CD25 depletion failed to impact on 
tumour growth or rejection. This was found to relate to a lack of target, with 
evidence of poor intra-tumoural T cell infiltration, likely related to the model 
(B16/BL6) and timing of GVAX/anti-CTLA-4 rather than either CD25-directed 
therapy. Whilst this is of potential relevance to non-inflamed human tumours, 
the study failed to provide any additional insights into the intra-tumoural 
activity of anti-CD25 mAbs. 
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Despite a lack of promising pre-clinical activity, CD25-directed approaches 
have undergone evaluation within small, predominantly early-phase clinical 
studies in the form of daclizumab (a humanised IgG1 murine anti-human 
CD25 antibody) or denileukin difitox (a recombinant fusion protein combining 
human IL-2 and a fragment of diptheria toxin) (Table 2) (Attia et al., 2005; 
Dannull, 2005; Jacobs et al., 2010; Janik et al., 2015; Luke et al., 2016; 
Mahnke et al., 2007; Rasku et al., 2008; Rech et al., 2012; Sampson et al., 
2012; Telang et al., 2011).  
 
Study&
 
Disease&se,ng Therapy Dose&and&scheduling Observa9ons Response&assessment 
A,a&et&al.&&
(J.&Immunother.&2005) 
Advanced(Melanoma(
RCC(
(n=13) 
Denileukin(Di8itox((DAB389IL@2)(
monotherapy(
 
9(or(18μg/kg(
OD(for(5(days(q.(21(days 
No(observed(depleQon(of(circulaQng(Treg(cells No(objecQve(responses 
Dannull&et&al.&&
(J.&Clin.&Invest.&2005) 
Advanced(RCC(&(
ovarian(
(n=11) 
Denileukin(Di8itox((DAB389IL@2)(
&(DC(vaccine 
Single(dose(at(18μg/kg SelecQve(eliminaQon(of(circulaQng(CD25hi(Treg(cells(
(
Improved(generaQon(of(vaccine@speciﬁc(eﬀector(T(
cells,(only(if(Denileukin(Di8itox((DAB389IL@2)(omiYed(
during(priming(
Not(assessed 
Mahnke&et&al.&
(Int&J&Cancer&2007) 
Advanced(melanoma(
(n=7) 
Denileukin(Di8itox((DAB389IL@2)(
&(MelanA/MART@1(vaccine 
5(or(18μg/kg(OD(for(3(days(prior(to(
vaccinaQon 
SelecQve(depleQon(of(circulaQng(Treg(cells(
(
Increase(in(melanoma(anQgen@speciﬁc(CD8’s. 
No(objecQve(responses(
(
1(stable(disease 
Rasku&et&al.&&
(J.&Transl.&Med.&2008) 
Advanced(melanoma(
(n=16) 
Denileukin(Di8itox(
(DAB389IL@2)(
monotherapy(
 
12μg/kg(OD(for(4(days(
q.(21(days 
Transient(depleQon(of(all(circulaQng(T(cell(subsets(
(
De(novo(appearance(of(melanoma@anQgen(speciﬁc(
CD8’s 
6(parQal(responses. 
Jacobs&et&al.&&
(Clin.&Cancer&Res.&2010) 
Advanced(melanoma(
(n=30) 
Daclizumab(&(DC(vaccinaQon Daclizumab(0.5mg/kg((
4(or(8(days(prior(to(DC(vaccinaQon 
DepleQon(of(all(circulaQng(CD25hi(T(cell(subsets((
(
ReducQon(in(vaccine@speciﬁc(eﬀector(T(cells(
No(impact(on(progression(
free(survival 
Telang&et&al.&&
(BMC&Cancer&2011) 
Advanced(melanoma(
(n=60) 
Denileukin(Di8itox((DAB389IL@2)(
monotherapy(
12μg/kg(OD(for(4(days(
q.(21(days(
Not(assessed 16.7%(parQal(responses(
(
5%(stable(disease(
(
15%(mixed(response 
Rech&et&al.&&
(Sci.&Transl.&Med.&2012) 
Advanced(breast(cancer(
(n=10) 
Daclizumab(+(hTERT(pepQde(
vaccine 
Daclizumab(1mg/kg(single(infusion,(
7(days(prior(to(vaccinaQon( 
Marked(reducQon(in(circulaQng(Treg(cells(
(
Robust(CD8/CD4(T(cell(priming(and(boosQng(to(all(
vaccine(anQgens 
Not(assessed 
Sampson&et&al.&&
(PloS&ONE&2012) 
Glioblastoma(
mulQforme(
(n=3) 
Daclizumab,(EGFRvIII(vaccine(&(
Temozolamide 
Single(infusion(of(daclizumab(at(
Qme(of(vaccinaQon 
ReducQon(in(frequency(of(circulaQng(Treg(cells(
(
Inverse(relaQonship(between(Treg(cell(frequency(and(
level(of(EGFRvIII@speciﬁc(humoral(responses 
Not(assessed 
Janik&et&al.&&
(Proc&Natl&Acad&Sci&U&S&A&&
2015) 
Relapsed/refractory(HL(
(n=46) 
90Y@daclizumab 10@15mCi(90Y@daclizumab(with(5mg(
unlabeled(daclizumab(
≤(7(infusions 
Signiﬁcant(reducQon(in(circulaQng(Treg(cells 14(complete(responses(
(
9(parQal(responses(
(
14(stable(disease 
Luke&et&al.&&
(J.&Immunother.&Cancer&
2016) 
Advanced(melanoma(
(n=17) 
Denileukin(Di8itox((DAB389IL@2)(
&(4@pepQde(vaccine 
Single(dose(at(18μg/kg(prior(to(
vaccinaQon(
(
No(change(in(circulaQng(Treg(cells(((
(
No(change(in(FoxP3(transcripts(in(one(tumour(biopsy(
(
No(increase(in(anQgen@speciﬁc(T(cells 
One(parQal(response(
(
8(stable(disease 
 
Table 2: Clinical studies of CD25-directed therapies in human cancer 
HL = Hodgkin lymphoma; OD = once daily and RCC = renal cell carcinoma 
 
The setting of these studies was consistently either in advanced solid cancer 
or refractory lymphoma. Direct comparison is challenging owing to varied 
dosing and scheduling of drug, particularly when given in combination with 
vaccination approaches. In the majority of studies, both Denileukin Diftitox 
(DAB389IL-2) and daclizumab effectively depleted circulating Treg cells and 
this was associated with either de novo or enhanced generation of antigen-
specific effector T cells. However, clinical responses were rare, raising the 
possibility that observations in blood may not be reflective of activity in the 
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tumour microenvironment. Similar to pre-clinical studies, limited evaluation of 
the tumour microenvironment was performed. On review of all studies, only 
one tumour biopsy was obtained following a single infusion of DAB389IL-2 
(Luke et al., 2016), analysis of this demonstrated no change in FoxP3 
transcripts relative to baseline, highlighting the importance of further study of 
the impact of such therapies on all compartments (blood, LN and tumour). 
 
Another potential explanation offered for the observed lack of activity against 
established tumours in mouse models and human tumours is that anti-CD25 
mAbs might also deplete CD25-expressing Teff cells generated upon antigen 
encounter with tumour, however such observations derive largely from in vitro 
studies, with little in vivo data to support this in pre-clinical or clinical studies 
(Boyman and Sprent, 2012).  
 
1.10 Re-evaluating CD25 as a therapeutic target 
Given the relevance of the antibody isotype, target molecule density and intra-
tumoural FcγR expression in the depleting activity of immune modulatory 
antibodies in mouse models (Bulliard et al., 2013, 2014; Dahan et al., 2015; 
Selby et al., 2013; Simpson et al., 2013), the second objective of this thesis 
was to dissect the in vivo activity of anti-CD25 mAbs (PC61 clone) through 
comprehensive analysis of blood, LN and tumour in mouse models of cancer 
with validation of the translational relevance of any findings in human tumour 
samples. 
 
1.11 Identification of drivers of T cell reactivity in human cancer 
The majority of current immunotherapeutic approaches against human cancer 
rely upon the presence of an existing immune infiltrate. To those studying the 
immune tumour microenvironment of human tumours, heterogeneity in 
immune infiltrate is well recognised and paucity or indeed complete absence 
of T cell infiltration is not an infrequent finding; although this is rarely 
acknowledged in the literature (Melero et al., 2014). Identification of the most 
relevant antigenic stimuli or drivers of T cell infiltrate therefore remains an 
area of high scientific priority.   
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1.12 Lessons from adoptive T cell therapy 
In humans, adoptive transfer of TILs with concomitant administration of 
interleukin-2 (IL-2) mediates tumour regression in 34-40% of patients with 
advanced melanoma (Rosenberg et al., 1988). This setting has provided a 
useful platform for characterisation of antigens eliciting T cell reactivity 
associated with clinical response (Gros et al., 2014; Tran et al., 2016). Early 
studies demonstrated melanoma TILs were able to recognise shared antigens 
on melanoma cell lines established from different patients, in a class I major-
histocompatibility complex (MHC)-restricted manner in vitro (Hom et al., 1993; 
Kawakami et al., 1992). The first gene identified to code for an antigen 
recognised on human tumours by autologous TILs was MAGE-1, silent in 
normal tissues except in testis, and expressed by a number of other solid 
tumour subtypes (van der Bruggen et al., 1991). Subsequently, three further 
self-proteins, all melanoma/melanocyte lineage-specific, encoded by MART-1, 
tyrosinase and gp100, were identified (Brichard et al., 1993; Coulie et al., 
1994; Kawakami et al., 1994). Although these ‘public’ tumour-associated 
antigens appeared attractive targets for both adoptive cell-based and 
vaccination strategies, neither approach has been observed to yield 
particularly promising activity in the clinical setting (June, 2007).  
 
The identification of CTLA-4, followed by the demonstration of efficient 
rejection of established murine tumours with CTLA-4 ‘blockade’, highlighted 
immune regulation as a potential contributor to the limited clinical activity of 
therapeutic strategies directed against these tumour-associated antigens 
(Brunet et al., 1987; Leach et al., 1996). In a pooled analysis of patients with 
advanced melanoma treated with ipilimumab, an antibody directed against 
CTLA-4, three-year survival was found to range between 20 and 26% 
(Schadendorf et al., 2015). Amongst a cohort of 107 patients with advanced 
melanoma, one of the earliest to be treated with nivolumab, an anti-PD-1 
antibody, 5-year survival was recently reported as 34% (Hodi S., AACR, 
2016). This is remarkable in a solid tumour subtype in which no therapy had 
prolonged survival prior to ipilimumab, however, it is important to 
acknowledge that the majority of patients do not respond to these forms of 
immune checkpoint blockade, at least as monotherapy. This has engendered 
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significant efforts to dissect underlying mechanisms of response within 
translational studies, with focus on tumours derived from patients responding 
to such therapies.  
 
1.13 Tumour-specific mutations serve as neoantigens 
A hallmark of tumours in patients that appear to derive benefit from 
checkpoint blockade with therapeutic CTLA-4 or PD-1 antibodies is pre-
existing T cell infiltration or an ‘inflamed’ tumour microenvironment (Huang et 
al., 2017; Ji et al., 2012; Tumeh et al., 2014). Tumour exome analysis in mice 
has revealed specific missense mutations that encode MHC class I presented 
mutational epitopes, capable of eliciting T cell-mediated tumour rejection 
(Castle et al., 2012; Matsushita et al., 2012). Tumour-specific mutations may 
therefore serve as ‘private’ neoantigens, eliciting anti-tumour T cell responses 
(Castle et al., 2012; Lu et al., 2013; Robbins et al., 2013; Segal et al., 2008). 
In contrast to non-mutated self antigens, these are thought to be of particular 
relevance in tumour control, since the quality of the T cell pool available for 
these antigens is not affected by central T cell tolerance (Gilboa, 1999). 
 
Brown and colleagues studied tumours from 515 patients, including 6 tumour 
subtypes, using RNA sequencing data derived from the The Cancer Genome 
Atlas (TCGA) (Brown et al., 2014). Mutations predicted to be immunogenic 
were identified based on their potential to give rise to mutational epitopes 
presented by MHC proteins encoded by each patient’s autologous HLA-A 
alleles. Mutational epitope burden demonstrated a positive association with 
survival. Tumours with a high burden of predicted mutational epitopes were 
observed to display a higher cytotoxic T lymphocyte content (based on CD8A 
gene expression) and elevated expression of co-inhibitory immune checkpoint 
molecules including PD-1 and CTLA-4. These findings were supported by 
even larger, elegant studies, confirming an inextricable relationship between 
the genomic landscape of tumours and anti-tumour immunity (Rooney et al., 
2015). 
 
It follows that response to immune checkpoint modulation might also depend 
upon mutational epitope burden. Two pivotal studies subsequently 
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demonstrated that patients with advanced melanoma and non-small cell lung 
cancer (NSCLC), deriving benefit from CTLA-4 and PD-1 blockade 
respectively, appeared to have tumours enriched with putative neoantigens 
(Rizvi et al., 2015; van Rooij et al., 2013; Snyder et al., 2014). However, in 
contrast to tumour-associated antigens, tumour-specific mutations appear 
unique to individual tumours. Analysis of 110 patients with advanced 
melanoma undergoing CTLA-4 blockade demonstrated an association 
between predicted neoantigen burden and clinical benefit, however no 
recurrent neoantigen peptide sequences were identified amongst responding 
patients (Van Allen et al., 2015).  
 
1.14 Identification and characterisation of neoantigen-reactive T cells 
Prediction of tumour-specific neoepitopes on an individual patient basis 
remains, at present, an unrealistic prospect for the majority of healthcare 
systems across the globe. However, whilst tumour-specific mutations vary 
between patients, the regulatory mechanisms underlying T cell activity are 
common to all. Circulating T cells have been demonstrated to recognise 
tumour-specific neoantigens in vitro (Rizvi et al., 2015; Snyder et al., 2014), 
however tumour-infiltrating neoantigen-reactive T cells are poorly described. 
The final objective of this study was to attempt to identify such cell subsets, 
determine phenotypic and functional markers by which they might be 
identified and characterise any regulatory mechanisms serving to limit their 
activity. 
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1.15 Aims  
 
• Characterisation of in vivo determinants of response to anti-
CTLA-4 antibodies in mouse and man 
 
• Re-evaiuation of CD25 as a therapeutic target for the selective 
depletion of Treg cells in mouse models and human cancers 
 
• Identification of novel drivers of T cell reactivity in human cancers 
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2 Materials and Methods 
 
2.1 Mice 
C57BL/6 and BALB/c mice were purchased from Charles River Laboratories.  
FcγRα null and human FcγR transgenic of C57BL/6 background (Smith et al., 
2012) mice were a kind gift from  J.V. Ravetch (The Rockefeller University, 
New York, USA), housed and bred in Charles River Laboratories, U.K.. 
Experiments were typically performed with 6-10 week old females.  
 
Fcer1g-/- and Fcgr3-/- mice were kindly provided by S. Beers (University of 
Southampton, UK). Fcgr4-/- and Fcgr2b-/- mice were a kind gift from J.V. 
Ravetch (The Rockefeller University, New York, USA). All knockout mice were 
of C57BL/6 background and bred in University College London. All animal 
studies were performed under University College London and UK Home 
Office ethical approval and regulations. 
 
2.2 Cell lines and tissue culture 
MCA205 cells were cultured in Dulbecco’s modified Eagle medium (DMEM, 
Sigma) supplemented with 10% foetal calf serum (FCS, Sigma), 100U/mL 
penicillin, 100µg/mL streptomycin and 2mM L-glutamine (all from Gibco). 
MC38, CT26, B16 and SupT1 cells were cultured in Roswell Park Memorial 
Institute (RPMI) media supplemented as above. K562 cells used for antibody 
production were cultured in phenol red-free Iscove’s Modified Dulbecco’s 
medium (IMDM) supplemented with 10% IgG-depleted FCS (Life 
Technologies). 
 
2.2.1 Generation of CTLA-4-expressing target cells  
A cell line with stable membrane-bound expression of murine CTLA-4 was 
generated by transduction of SupT1 cells with a retroviral vector (a kind gift 
from Claire Roddie, University College London). CTLA-4 expression was 
confirmed prior to assays by flow cytometry. 
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2.2.2 Generation of monocyte-derived human macrophages 
Monocytes were isolated from healthy donor PBMCs with use of anti-CD14 
microbeads (Miltenyi Biotec) and cultured for 7 days in RPMI supplemented 
with 10% FCS and recombinant human macrophage colony-stimulating factor 
(M-CSF, CELL guidance systems) at 40ng/mL. Additional media was added 
every 48 hours as required. The final phenotype and Fc gamma receptor 
expression profile of macrophages was determined by flow cytometry on day 
7. 
 
2.2.3 Carboxyfluorescein succinimidyl ester (CFSE) labelling  
CFSE was used to label target cells employed within ADCC assays. Cells 
were resuspended at 5x106/mL in PBS/0.1% bovine serum albumin (BSA) 
and labeled with 5µM CFSE (CellTrace CFSE Cell Proliferation Kit, Life 
Technologies). To obtain a 5µM solution of CFSE, 2µL CFSE was 
resuspended in 1mL of warm PBS/BSA 0.1%. 1mL of diluted CFSE was 
added to target cells and mixed thoroughly to obtain homogeneous staining 
prior to incubation at 37°C for 10 minutes. The reaction was then immediately 
quenched, by adding 5 volumes of cold RPMI and incubating for 5 minutes on 
ice. In order to minimise cell toxicity and to obtain clean labeling, 4 wash steps 
were then performed prior to use. 
 
2.2.4 Antibody production 
 
2.2.4.1 Anti-CTLA-4  
Antibody production was outsourced to Evitria AG (Switzerland). The 
sequence of the variable regions of the heavy and light chains of anti-mouse 
CTLA-4, clone 4F10, was kindly provided by J.A. Bluestone and used to 
generate chimeric antibodies with the constant regions of human IgG1 and 
IgG2 heavy chains and κ light chain, as well as the mutated IgG1 variants 
N297A and S239D/A330L/I332E (SDALIE) (Lazar et al., 2006). 
 
2.2.4.2 Anti-CD25  
The sequence of the variable regions of the heavy and light chains of anti-
CD25 were resolved from the PC-61.5.3 hybridoma by rapid amplification of 
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cDNA ends (RACE) and then cloned into the constant regions of murine 
IgG2a and κ chains sourced from the pFUSEss-CHIg-mG2A and pFUSE2ss-
CLIg-mk plasmids (Invivogen). Each antibody chain was then sub-cloned into 
a murine leukaemia virus (MLV)-derived retroviral vectors used to generate 
K562 stable cell lines. For preliminary experiments, antibody was purified from 
supernatants with a protein G HiTrap MabSelect column (GE Healthcare), 
dialysed in phosphate-buffered saline (PBS), concentrated and filter-sterilised. 
For subsequent experiments, antibody production was outsourced to Evitria 
AG (Switzerland).  
 
2.2.5  In vitro ADCC assay 
SupT1 cells expressing murine CTLA-4 were labelled with 10µM CFSE 
(CellTrace CFSE Cell Proliferation Kit, Life Technologies) and co-cultured 
overnight with human macrophages at the indicated ratios in the presence of 
the indicated mAbs (50µg/mL) (Figure 3). The absolute number of CFSE-
labelled cells in each condition was then quantified by flow cytometry using a 
defined number of fluorescent beads (Cell Sorting Set-up Beads for UV 
Lasers, ThermoFisher) as reference. The percentage of killing was 
determined as: 100-(number CFSE+ targets treated/number CFSE+ targets 
untreated). 
 
Figure 3: 96 well plate design of in vitro ADCC assay 
Therapeutic antibodies are displayed above. Each condition was performed in triplicate. 
Control wells consisted of CTLA-4-expressing SupT1 target cells and therapeutic mAbs 
alone. Depicted ratios are of effector (macrophages) to target cell (SupT1s). 
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2.3  Mouse tumour experiments 
Cultured tumour cells were trypsinised, washed, re-suspended in 100uL of 
PBS and injected subcutaneously (s.c.) in the flank. Therapeutic antibodies 
were injected intra-peritoneally at the time points and doses detailed in the 
figure legends. Tumours were measured twice weekly and volumes calculated 
as the product of three orthogonal diameters. Mice were euthanized when any 
diameter reached 150mm.  
 
2.3.1 Processing of mouse tissue for immunological analyses 
Mice were sacrificed at specified time points with CO2. Lymph nodes 
(inguinal, axillary and brachial) and tumours were dissected into RPMI. Lymph 
nodes were dispersed through a 70µm filter, whereas tumours were 
mechanically disrupted using scissors, digested with a mixture of 0.33 mg/ml 
DNase (Sigma) and 0.27mg/ml Liberase TL (Roche) in serum free RPMI for 
25 minutes, and dispersed through a 70µm filter. 
 
2.3.2 Therapeutic antibodies 
Commercial anti-CD25 (clone PC-61.5.3) and anti-CTLA-4 (clone 9H10) 
mAbs used for in vivo experiments were purchased from BioXcell (USA). The 
binding affinity of different isotype variants to FcγRs was measured by surface 
plasmon resonance in the Ravetch laboratory as described previously 
(Nimmerjahn and Ravetch, 2005). 
 
2.4 Human tumour experiments 
 
2.4.1 Study oversight 
Presented human data derives from three translational studies, each 
approved by local institutional review board and Research Ethics Committee 
(Melanoma - REC no. 11/LO/0003, NSCLC – REC no.13/LO/1546, RCC – 
REC no. 11/LO/1996).  All were conducted in accordance with the provisions 
of the Declaration of Helsinki and with Good Clinical Practice guidelines as 
defined by the International Conference on Harmonization. All patients (or 
their legal representatives) provided written informed consent before 
enrolment.  
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2.4.2 Patient identification and tumour sampling 
Patients were identified in the clinic and consented to relevant studies. 
Tumour samples and peripheral blood were obtained directly from the 
operating theatre. Sampling of tumour representative and normal tissue areas 
was performed under the supervision of a Consultant Pathologist. Fresh 
tissue was placed in RPMI supplemented with 10% FCS and transported at 
room temperature to the wet laboratory. 
 
2.4.3 Patient selection and demographics 
The human data presented in this study derives from distinct patient cohorts 
identified to address specific scientific questions. 
 
2.4.3.1 Cohort 1 – T cell profiling 
Numerous patient samples were evaluated over the course of this study. For 
T cell analyses, data is presented from an experiment including patients with 
advanced melanoma (Table 3), early NSCLC (Table 4) and varied-stage RCC 
(Table 5). This was performed to allow direct comparison between tumour 
subtypes. 
 
Melanoma samples derived from patients with stage III/IV disease undergoing 
palliative resections. Patients were either treatment naïve or had progressed 
through varied systemic therapies. In contrast, non-small cell lung cancer 
samples derived from patients undergoing resection of primary lung cancers; 
no patient had received any form of neoadjuvant therapy. Renal cell 
carcinoma samples derived predominantly from patients with clear cell 
histology undergoing cytoreductive surgery. All were treatment naive and 
most commonly of advanced stage.  
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Iden%ﬁer( Age( Sex( Subtype( Stage( Biopsy(
site(
Muta%onal(
status(
Current(
therapy(
Previous(therapy(
MM1( 53% M% Cutaneous% IIIc% LN% BRAF%WT%%NRAS%mutant% Nil%
Adjuvant%
ipilimumab/
nivolumab%
MM2( 52% M% Cutaneous% IV%–%M1c%
Small%
bowel% BRAF%mutant% Pembrolizumab% Ipilimumab%
MM3( 76% F% Cutaneous% IV%–%M1c%
Small%
bowel%
BRAF%WT%
NRAS%mutant% Nil% Nil%
MM4( 76% M% Cutaneous% IIIc% LN% BRAF%mutant%% Nil% Nil%
MM5( 74% F% Cutaneous% IV%–%M1a% LN% BRAF%WT% Nil% Nil%
MM6( 61% M% Cutaneous% IV%–%M1a% LN% BRAF%WT% Nil% Ipilimumab%
MM7( 42% M% Cutaneous% IIIc% LN% BRAF%mutant% Nil% Nil%
MM8( 49% M% Cutaneous% IV%–%M1c% LN%
BRAF%WT%
NRAS%mutant% Nil%
Paclitaxel%
TrameOnib%%
Ipilimumab%
Pembrolizumab%  
 
Table 3: Demographics and baseline characteristics of patients with advanced 
melanoma (M, male; F, female; LN, lymph node)  
 
 
Iden%ﬁer( Age( Sex( Subtype( Stage( Resec%on(site(s)( Current(therapy(
Previous(
therapy(
NSCLC1&
( 74& M& Adenocarcinoma& IIa&
Right&lower&
lobe& Nil& Nil&
NSCLC2& 76& M& Squamous& IIIa& Right&upper&lobe&
Nil&&
& Nil&
NSCLC3& 53& F& Squamous&& IIa&
LeE&upper&
lobe&
Nil&
& Nil&
NSCLC4& 90& M& Squamous&& IIa&
LeE&lower&
lobe& Nil& Nil&
NSCLC5& 60& M& Adenocarcinoma& IIa& LeE&upper&lobe& Nil& Nil&
NSCLC6& 57& M& Adenocarcinoma& IIb& LeE&lower&Lobe&
Nil&
& Nil&
NSCLC7&
( 54& F&
Adenocarcinoma&
& IIa&
Right&upper&
lobe&
Nil&
&
Nil&
&
NSCLC8( 69& M& Adenocarcinoma& Ia& LeE&lower&lobe& Nil& Nil&  
 
Table 4: Demographics and baseline characteristics of patients with early-stage 
NSCLC (M, male; F, female)  
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Iden%ﬁer( Age( Sex( Subtype( Stage( Current(therapy( Previous(therapy(
RCC1( 44% M% Clear%cell% III% Nil% Nil%
RCC2( 69% M% Clear%cell% IIa% Nil% Nil%
RCC3( 78% F% Mixed%8%clear%cell/%tubulo8papillary% Ia% Nil% Nil%
RCC4( 65% F% Clear%cell% IV% Nil% Nil%
RCC5( 50% F% Clear%cell% IV% Nil% Nil%
RCC6( 60% F% Clear%cell% IV% Nil% Nil%
RCC7( 19% F% Clear%cell% IV% Nil% Nil%
RCC8( 59% M% Clear%cell% IV% Nil% Nil%
 
Table 5: Demographics and baseline characteristics of patients with varied stage renal 
cell carcinoma (M, male; F, female)  
 
2.4.3.2 Cohort 2 – myeloid cell profiling  
Preliminary data demonstrated that cryopreservation impacted negatively 
upon a number of FcγR-expressing cell subsets particularly granulocytes. 
FcγR profiling therefore required a separate cohort of patients. Analyses were 
performed exclusively on freshly isolated resection specimens of advanced 
melanoma derived from multiple anatomical sites including subcutaneous, 
small bowel, lymph node and splenic metastases (Table 6). Pathology 
guidance was particularly important in this setting to ensure sampling of bona 
fide tumour-representative areas. 
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Iden%ﬁer( Age( Sex( Subtype( Stage( Biopsy(site(
Muta%onal(
status(
Current(
therapy(
Previous(
therapy(
Myeloid(1( 66( M( Cutaneous( IV(M1c( LN( BRAF(WT( Pembrolizumab( Ipilimumab(
Myeloid(2( 60( M( Ocular( IV(M1c(
Splenic(
metastasis(
BRAF(WT(
( Nil( Nil(
Myeloid(3( 76( M( Cutaneous( IV(M1c( SC( BRAF(mutant( Nil( Nil(
Myeloid(4( 86( F( Cutaneous( IV(M1c( SC( BRAF(WT( Nil( Nil(
LN(
Myeloid(5( 46( F( Cutaneous( IV(M1c( SC( BRAF(mutant( Nil(
Dabrafenib/
TrameNnib(
Myeloid(6( 50( M( Cutaneous( IV(M1c(
Small(
bowel( BRAF(mutant( Pembrolizumab( Ipilimumab(
Myeloid(7( 69( M( Cutaneous( IV(M1c( SC( BRAF(WT( Pembrolizumab( Ipilimumab(
Myeloid(8( 76( F( Cutaneous( IV(M1c(
Small(
bowel( BRAF(WT( Nil( Nil(
Myeloid(9( 53( M( Cutaneous( IIIc( LN( BRAF(WT( Nil(
Adjuvant(
ipilimumab/
nivolumab(  
Table 6: Demographics and baseline characteristics of patients with advanced 
melanoma undergoing FcγR profiling (M, male; F, female; LN, lymph node; SC, 
subcutaneous)  
 
2.4.3.3 Cohort 3 - longitudinal analyses 
Longitudinal assessment of the tumour microenvironment was performed via 
image-guided core biopsy of the same primary or metastatic site following 4 
cycles of either nivolumab (3mg/kg Q2W) in advanced RCC, or 2 cycles of 
pembrolizumab (200mg Q3W) in patients with advanced melanoma (Table 7). 
Samples were obtained by the interventional radiology team and underwent 
formalin fixation and paraffin embedding. Cut slides were analysed by 
multiplex immunohistochemistry (IHC).  
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Pa#ent Age Sex Subtype Stage Biopsy3site Muta#onal3
status 
Current33
therapy 
Previous3
therapy 
CB1 64 M Cutaneous.
melanoma 
IV.–.M1c SC BRAF.WT Pembrolizumab Ipilimumab 
CB2 54 M Cutaneous.
melanoma 
IV.–.M1c SC BRAF.mutant Pembrolizumab Ipilimumab 
CB3 32 F Cutaneous.
melanoma 
IV.–.M1c SC BRAF.WT.
NRAS.WT 
Pembrolizumab Ipilimumab 
CB4 69 F Cutaneous.
melanoma.
IV.–.M1c LN BRAF.mutant.
NRAS.WT 
Ipilimumab.+.
Nivolumab 
Nil 
CB5 62 M Clear.cell.RCC IV Adrenal.
metastasis 
.
J.
Nivolumab Nil 
CB6 53 M Clear.cell.RCC. IV Primary.
renal.mass 
.
J 
Nivolumab. Nil 
 
Table 7: Demographics and baseline characteristics of patients with advanced 
melanoma and RCC undergoing PD-1 blockade (M, male; F, female; LN, lymph node; SC, 
subcutaneous)  
 
2.4.3.4 Cohort 4 – identification of neoantigen-reactive T cells 
Two patients undergoing resection of primary lung tumours were studied; 
L011 and L012. Demographics and baseline characteristics are displayed in 
Figure 23. Resection specimens were subjected to multi-regional sampling by 
the Swanton laboratory team under the supervision of a Consultant 
Pathologist as described previously (de Bruin et al., 2014; Jamal-Hanjani et 
al., 2017). 
 
2.4.4 Preparation of human samples for immunological analyses 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood 
obtained at venesection following gradient centrifugation with Ficoll-paque 
(GE Healthcare). Tumour samples were digested with Liberase TL 
(0.3mg/mL, Roche) and DNAse I (0.2 mg/mL, Roche) at 37°C for 30 minutes, 
homogenised using gentleMACS (Miltenyi Biotech) and filtered through a 
0.7µm cell mesh. Leukocytes were enriched by gradient centrifugation with 
Ficoll-paque (GE Healthcare). Isolated live cells were analysed immediately 
for FcγR profiling or frozen at  -80°C and stored in liquid nitrogen until 
analysis.  
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2.4.5 In-vitro expansion of tumour-infiltrating lymphocytes  
For high-throughput screening with MHC multimers, human TILs were 
expanded with use of a rapid expansion protocol (REP) in T25 flasks 
containing EX-VIVO media (Lonza) supplemented with 10% human AB serum 
(Sigma), soluble anti-CD3 (OKT3, BioXCell), 6000IU/mL recombinant human 
(rhIL-2, PeproTech) and 2x107 irradiated PBMCs (30Gy) pooled from 3 
allogeneic healthy donors. Fresh media containing rhIL-2 at 6000IU/mL was 
added every three days as required. Following 2 weeks of expansion, TILs 
were counted, phenotyped by flow cytometry and frozen in human AB serum 
(Sigma) at -80°C before use in relevant assays or long-term storage in liquid 
nitrogen. 
 
2.4.6 Preparation of human samples for genomic analyses 
Multi-regional sampling, DNA extraction and whole exome sequencing was 
led and performed by the Swanton laboratory. Relevant methodology has 
been previously described in full (de Bruin et al., 2014; Jamal-Hanjani et al., 
2017). 
 
2.5 Flow cytometry analyses 
Cell surface staining was performed in round-bottomed 96 well plates. 
Surface antibodies were applied for 30 minutes in the dark, on ice, using cold 
buffers and reagents, followed by a double wash in staining buffer (PBS, 2% 
FCS and 0.1% sodium azide) supplemented with 10% superblock (500uL rat 
serum, 500uL mouse serum +/- mouse/human FcγR block). Intracellular 
staining was performed using the FoxP3 Transcription Factor Staining Buffer 
Set (eBioscience). For quantification of absolute number of cells, a defined 
number of fluorescent beads (Cell Sorting Set-up Beads for UV Lasers, 
ThermoFisher) was added to each sample before acquisition and used as a 
counting reference. Antibodies used for staining of mouse and human cells 
are displayed in Table 8 and Table 9 respectively. 
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Antibody Clone Supplier 
CD4-V500 RM4-5 BD Biosciences 
CD25-FITC 7D4 BD Biosciences 
CD4-BrilliantViolet785 RM4-5 BioLegend 
CD8-BrilliantViolet650 53-6.7 BioLegend 
CD19-BrilliantViolet605 6D5 BioLegend 
CD3-BrilliantViolet785 17A2 BioLegend 
CD64-APC X54-5/7.1 BioLegend 
OX40-biotin OX86 BioLegend 
Streptavidin-
BrilliantViolet605 
 
- 
BioLegend 
Streptavidin-
BrilliantViolet705 
 
- 
BioLegend 
Anti-CD16/32- 
AlexaFluor488  
2.4G2 BioXcell 
CD3-PE.Cy7 145-2C11 eBioscience 
CD5-PerCP.Cy5.5 53-7.3 eBioscience 
FoxP3-FITC FJK-16s eBioscience 
I-Ab-eFluor450 AF6-210.1 eBioscience 
NK1.1-AlexaFluor700 PK136 eBioscience 
NK1.1-BrilliantViolet650 PK136 eBioscience 
Ki67-eFluor450 SolA15 eBioscience 
GITR-eFluor450 DTA-1 eBioscience 
4-1BB-biotin 17B-5 eBioscience 
PD-1-eFluor450 RMP1-30 eBioscience 
TIM-3-PE 8B.2C12 eBioscience 
PD-1-PERCP.Cy5.5 J43 eBioscience 
FoxP3-PE FJK-16s eBioscience 
CD5-eFluor450 53-7.3 eBioscience 
CD11b-PERCP-Cy5.5 M1/70 eBioscience 
FcγRIV- AlexaFluor488 9E9.27 Ravetch laboratory 
CD32b- AlexaFluor647 K9.361 Ravetch laboratory 
 
Table 8: Antibodies used for staining of mouse cells 
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Antibody Clone Supplier 
Ki67-FITC B56 BD Biosciences 
CD8-V500 SK1 BD Biosciences 
CD64-AF700 10.1 BD Biosciences 
CD16a/b-V500 3G8 BD Biosciences 
Granzyme B-V450 GB11 BD Biosciences 
TIM-3-Q650 7D3 BD Biosciences 
CD14-PE-Cy7 M5E2 BD Biosciences 
CD32b-APC 6-G11 BioInvent 
CD11c-V450 3.9 BioLegend 
CD45-Q655 HI30 BioLegend 
CD56-BV711 HCD56 BioLegend 
CD19-BV785 HIB19 BioLegend 
CD11b-PerCP-Cy5.5 ICRF44 BioLegend 
CD15-PE HI98 BioLegend 
PD-1-Q605 EH12.2H7 BioLegend 
CD25-BV711 BC96 BioLegend 
CD3-BV785 OKT3 BioLegend 
BTLA-PerCP-Cy5.5 MIH26 BioLegend 
CTLA-4-APC L3D10 BioLegend 
Streptavidin-Q650 - BioLegend 
OX40-PE-Cy7 ACT35 BioLegend 
ICOS-APC C398.4A BioLegend 
4-1BB-PE 4B4-1 BioLegend 
CD3-BrilliantViolet785 OKT3 BioLegend 
CD25-BrilliantViolet650 BC96 BioLegend 
LAG-3-PE-Cy7 3DS223H eBioscience 
TIGIT-FITC MBSA43 eBioscience 
CD3-e605 OKT3 eBioscience 
Anti-CD4-AlexaFluor700 OKT4 eBioscience 
Anti-FoxP3-PerCP-
Cy5.5 
PCH101 eBioscience 
HLA-DR-PE L243 eBioscience 
Fixable viability dye-
e780 
- eBioscience 
GITR-Biotinylated DT5D3 Miltenyi 
CD32a-FITC IV.3 StemCell 
 
Table 9: Antibodies used for staining of human cells 
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2.6 MHC multimer generation and combinatorial encoding-flow 
cytometry analysis  
MHC multimers holding the predicted neoepitopes were produced in-house at 
Technical University of Denmark, Hadrup laboratory. Synthetic peptides were 
purchased at Pepscan Presto, NL.  HLA molecules matching the HLA-
expression of L011 (HLA-A1101, A2402, and B3501) and L012 (HLA-A1101, 
A2402, and B0702) were refolded with a UV-sensitive peptide, and 
exchanged to peptides of interest following UV exposure (Bakker et al., 2008; 
Chang et al., 2013; Frøsig et al., 2015; Toebes et al., 2006). HLA complexes 
loaded with UV-sensitive peptide were subjected to 366-nm UV light 
(CAMAG) for one hour at 4°C in the presence of candidate neoantigen 
peptides in a 384-well plate. Peptide-MHC multimers were generated using a 
total of 9 different fluorescent streptavidin (SA) conjugates: PE, APC, PE-Cy7, 
PE-CF594, Brilliant Violet (BV)421, BV510, BV605, BV650, Brilliant Ultraviolet 
(BUV)395 (BioLegend). MHC multimers were generated with two different 
streptavidin-conjugates for each peptide-specificity to allow a combinatorial 
encoding of each antigen responsive T cell, enabling analyses for reactivity 
against up to 36 different peptides in parallel (Andersen et al., 2012; Hadrup 
et al., 2009). 
 
2.6.1 Screening of in-vitro-expanded tumour-infiltrating CD8+ T cells 
In-vitro expanded CD8+ T lymphocytes isolated from region-specific lung 
cancer samples and adjacent normal lung tissue were screened with MHC 
multimers bearing mutant peptides (with predicted HLA binding affinity 
<500nM, including multiple potential peptide variations from the same 
missense mutation) in patient L011 and L012 respectively. Simultaneously, 
TIL responses to HLA-matched viral peptides were assessed, demonstrating 
functionality of the employed MHC-multimer technology. Viral peptides 
screened for L011 and L012 are displayed (Table 10). Reactivity of healthy 
donor CD8+ PBMC’s against the same peptides was also assessed, in order 
to demonstrate a lack of background/non-specific staining.  
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L011 L012 
A11 EBV-EBNA4 (AVFDRKSDAK) A11 EBV EBNA4 (AVFDRKSDAK) 
A11 HCMV pp65 (GPISGHVLK) A11 HCMV pp65 (GPISGHVLK)  
A24 EBV LMP-2 419-427 (TYGPVMCL) A24 EBV EBNA-3 114-121 (RYSIFFDY)  
A3 EBV EBNA 3A RLR (RLRAEAQVK)  A24 EBV LMP-2 419-427 (TYGPVFMCL)  
A24 HCMV 248-256 (AYAQKIFKIL)  A24 EBV RTA 28-37 (DYCNVLNKEF)  
B35 Flu Matrix (ASCMGLIY)  A24 HCMV 248-256 (AYAQKIFKIL)  
B35 ENV EBNA 3B (AVLLHEESM) B7 CMV pp65 RPH-L (RPHERNGFTV)  
EBV EBNA-3 114-121 (RYSIFFDY)  B7 CMV pp65 TPR (TPRVTGGGAM)  
EBV BZLF1 (APENAYQAY) B7 EBV EBNA RPP (RPPIFIRLL)  
 
Table 10: Control HLA-matched viral peptides 
 
For staining of in-vitro expanded CD8+ T lymphocytes, samples were thawed, 
treated with DNAse for 10 minutes, washed and stained with MHC multimer 
panels for 15 minutes at 37°C. Subsequently, cells were stained with 
LIVE/DEAD® Fixable Near-IR Dead Cell Stain Kit for 633 or 635 nm 
excitation (Invitrogen, Life Technologies), CD8-PerCP (Invitrogen, Life 
Technologies) and FITC coupled antibodies to a panel of CD4, CD14, CD16, 
CD19 (all from BD Pharmingen) and CD40 (AbD Serotec) for an additional 20 
minutes at 4°C. Cut off values for the definition of positive responses were 
≥0.005% of total CD8+ cells and ≥10 events.  
 
2.6.2 Screening and characterisation of non-expanded tumour-
infiltrating T cells 
Tumour samples were thawed, washed and first stained with custom-made 
MHC multimers for 10-15 minutes at 37°C. Cells were thereafter transferred 
onto wet ice and stained for 30 minutes with a panel of surface antibodies 
used at the manufacturer’s recommended dilution: CD8-V500, SK1 clone (BD 
Biosciences), PD-1-BV605, EH12.2H7 clone (Biolegend), CD3-BV785, OKT3 
clone (Biolegend), LAG-3-PE, 3DS223H clone (eBioscience). A fixable 
viability dye (eFlour780, eBioscience) was included in the surface mastermix. 
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Cells were permeabilised for 20 minutes with use of an intracellular fixation 
and permeabilisation buffer set from eBioscience. An intracellular staining 
panel was applied for 30 minutes and consisted of the following antibodies 
used at the manufacturer’s recommended dilution: granzyme B-V450, GB11 
clone (BD Biosciences), FoxP3-PerCP-Cy5.5, PCH101 clone (eBioscience), 
Ki67-FITC, clone B56 (BD Biosciences) and CTLA-4 – APC, L3D10 clone 
(Biolegend).  
 
2.7 Data acquisition 
All flow cytometry data acquisition was performed with use of a BD LSR II 
Fortessa (BD Biosciences).  
 
2.8  Multiplex immunohistochemistry (IHC) 
2-5µm tissue sections of formalin-fixed and paraffin-embedded tumour 
samples were cut and stained with the following antibodies: anti-CD8 
(SP239), anti-FoxP3 (236A/E7) (a gift from Dr. G. Roncador CNIO, Madrid, 
Spain) and anti-CD25 (4C9) (Leica Biosystems). Dilutions were optimised with 
single conventional immunostaining of human tonsil sections. For multiple 
staining, tissue sections were incubated with the primary antibodies for 30 
minutes after antigen retrieval by heating and endogenous peroxidase 
blocking (DakoCytomation). Detection was performed using the peroxidase-
based detection reagent conjugate (OptiView DAB IHC Detection Kit) followed 
by the alkaline phosphatase detection kit (UltraView Universal Alkaline 
Phosphatase Red Detection Kit), both from Ventana Medical Systems, Inc.. 
The immuno-complexes were visualized with either Fast Red or Fast Blue if 
used previously, or vice versa. Cell counting was performed with use of 
ImageJ (1.48v). 
 
2.9  Bioinformatics analyses  
Bioinformatics analyses were performed by the Swanton laboratory, detail on 
relevant methodology is provided below courtesy of Nicholas McGranahan 
and Rachel Rosenthal, this has also been described elsewhere (McGranahan 
et al., 2016). 
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2.9.1 Variant calling 
Analysis of germline, primary tumour regions and variant calling from 
previously published cohorts was performed by the Swanton laboratory and 
has previously been described in full (de Bruin et al., 2014; Jamal-Hanjani et 
al., 2017; McGranahan et al., 2016). 
 
2.9.2 Clonal architecture analysis  
The clonal status of each mutation was estimated based on multi-region 
sequencing calls. In brief, each mutation was classified as clonal if identified 
and present in each and every tumour region sequenced within the tumour. 
Conversely, any mutations not ubiquitously present in every tumour region 
were classified as subclonal. For single sample sequenced tumours, a 
modified version of PyClone was used. This modification was implemented to 
allow clustering on mutations occurring in regions of subclonal copy number.  
 
2.9.3 HLA typing of patient samples 
For all TCGA patients, the 4-digit HLA type was determined using 
POLYSOLVER (POLYmorphic loci reSOLVER) (Shukla et al., 2015). Patients 
L011 and L012 were serotyped (outsourced to Anthony Nolan, London) and 
simultaneously genotyped using Optitype (Szolek et al., 2014), which 
produced concordant results.  
 
2.9.4 Identification of putative neoantigens 
Identified non-silent mutations were used to generate a comprehensive list of 
peptides 9-11 amino acids in length with the mutated amino acid represented 
in each possible position. The binding affinity of every mutant peptide and its 
corresponding wild-type peptide to the patient’s germline HLA alleles was 
predicted using netMHCpan-2.8 (Hoof et al., 2009; Nielsen et al., 2007).  
Candidate neo-antigens were identified as those with a predicted binding 
strength of <500 nM. 
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2.9.5 TCGA exome datasets 
 
Tumour samples, with mutation calls and HLA typing described below, were 
obtained from the Cancer Genome Atlas (TCGA) for a cohort of lung 
adenocarcinoma patients (LUAD, n=150). SNV data was obtained from 
TumorPortal (Lawrence et al., 2014) for the LUAD. One LUAD patient, TCGA-
05-4396, was excluded for having over 7000 low quality mutations called, 
mostly in a C[C>G]G context.  
 
2.9.6 TCGA survival analysis 
Clinical data for the TCGA patients was accessed through the TCGA data 
portal. Patients were first grouped according to quartile of the variable being 
considered. Survival analyses were then performed in R using the survival 
package. Complete survival data was available for 139/150 LUAD patients. 
 
2.9.7 Differential gene expression analysis 
RNA-sequencing data was downloaded from the TCGA data portal. For each 
LUAD sample, all available ‘Level_3’ gene-level data was obtained.  The raw 
read counts were used as input into the R package DESeq2 for analysis.  
Transcriptome-wide differential gene expression analyses were performed 
between all TCGA LUAD tumours and between high and low clonal 
neoantigen TCGA LUAD groups. Significantly differentially expressed 
immune-related genes were identified.  These genes were clustered on their 
co-expression using the metric 1-r2. 
 
2.10 Statistical analyses 
Flow cytometry data analysis was performed in FlowJo version 10.0.8 (Tree 
Star Inc.). Statistical analyses were performed in Prism 6 (GraphPad 
Software, Inc.); p values were calculated using Kruskall-Wallis analysis of 
variance and Dunn’s post-hoc test, unless otherwise indicated in the figure 
legends (ns = p > 0.05; * = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 
0.0001). Analysis of the significance of differentially expressed immune-
related genes was performed with use of Wald’s test. Analysis of Kaplan-
Meier survival curves was performed with use of the log-rank test.  
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3 Results 1: Dissecting the in vivo activity of anti-CTLA-4 antibodies 
 
3.1  Introduction 
Pre-clinical data in mouse models of cancer clearly demonstrate that in 
addition to blockade of a co-inhibitory molecule, anti-CTLA-4 mAbs act to 
deplete intra-tumoural Treg cells expressing high levels of surface CTLA-4 via 
ADCC (Bulliard et al., 2013; Selby et al., 2013; Simpson et al., 2013). In 
mouse models, this activity is required for maximal efficacy, however 
demonstrating a common mechanism in human cancers has proved 
challenging. The first objective of this thesis was to attempt evaluate this 
further through: 
(i) comprehensive evaluation of CTLA-4 expression in circulating and 
tumour-infiltrating T cell subsets in mouse models and human cancers  
(ii) profiling of activatory and inhibitory FcγRs on circulating and tumour-
infiltrating lymphocyte and innate effector cell subsets in mouse models 
and human cancers  
(iii) attempting to bridge the translational void with use of chimeric anti-
mouse CTLA-4 mAbs with human Fc variants within a transgenic mouse 
model bearing human FcγRs  
(iv) confirm the translational relevance of in vivo findings through in silico 
analysis of tumour exomes in patients treated with anti-CTLA-4 mAb 
In vivo mouse work was performed by Fred Arce Vargas. Ex vivo work 
was performed together with Andrew Furness. Study of human samples 
was performed independently by Andrew Furness. Bioinformatics analyses 
were led and interpreted by Andrew Furness; data was generated by 
Rachel Rosenthal. 
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3.2  Identification of circulating and tumour-infiltrating T cell subsets 
in human cancers 
Analysis of immune checkpoint molecule expression in human tumour 
samples is often largely focused on CD8+ T cells (Gros et al., 2014). Given 
the differential expression of CTLA-4, OX40 and GITR observed in mouse 
models of cancer (Bulliard et al., 2013, 2014; Selby et al., 2013; Simpson et 
al., 2013), the prevalence of individual T cell subsets within the peripheral 
blood and tumours of patients with solid tumours was studied. 
 
Isolated peripheral blood mononuclear cells (PBMCs) and tumour digests 
were analysed by multi-parametric flow cytometry (Figure 4). Single, live, 
CD3+ T cells were identified before application of further gating to distinguish 
between CD4+FoxP3+ regulatory T cells (Treg), CD4+FoxP3- and CD8+ 
effector T cells (Teff) (Figure 4A). Relative frequencies of both circulating and 
tumour-infiltrating T cell subsets were compared across a cohort of patients 
with advanced melanoma, early-stage NSCLC and RCC of varied stage 
(Figure 4B, Chapter 2.4.3.1, Materials and Methods). 
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Figure 4: Identification of circulating and tumour-infiltrating T cell subsets in human 
cancers  
Matched peripheral blood mononuclear cells (PBMC) and tumour digests were analysed by 
multi-parametric flow cytometry. (A) Gating strategy for identification of CD8+ and 
CD4+FoxP3- effector T cells (Teff) and CD4+FoxP3+ regulatory T cells (Treg). (B) The 
relative frequency of T cell subsets in blood (PBMC) and tumour in patients with advanced 
melanoma (n=8), NSCLC, (n=8) and renal cell carcinoma (n=8). 
 
In tumours, the frequency of CD4+FoxP3- T cells was consistently lower than 
in blood (mean % CD4eff of total CD3+ cells in PBMC: melanoma=64.7%, 
NSCLC=60.5% and RCC=58.1% vs. tumour: melanoma=39.1%, 
NSCLC=38.2% and RCC=44.4%). In contrast, the frequency of CD8+ T cells 
in tumours was either higher or comparable to blood (mean % CD8+ of total 
CD3+ cells in PBMC: melanoma=24.4%, NSCLC=33.6% and RCC=32.2% vs. 
tumour: melanoma=38.7%, NSCLC=33.4% and RCC=34.5%). Notably, 
across all three tumour subtypes, an increase in frequency of tumour-
infiltrating Treg was observed relative to blood (mean % Treg of total CD3+ 
cells in blood: melanoma=3.8%, NSCLC=3.5% and RCC=2.7% vs. tumour: 
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melanoma=13%, NSCLC=19.6% and RCC=9.2%), suggesting that these cells 
are enriched in the tumour microenvironment and may represent an attractive 
target for therapeutic intervention.  
 
3.3  CTLA-4 is expressed at high levels on tumour-infiltrating Treg 
cells in mouse and man 
CTLA-4 has been described to be constitutively expressed on Treg cells 
(Read et al., 2000, 2006; Wing et al., 2008) and emerging data suggest this 
may also be relevant to Treg cells infiltrating human tumours (De Simone et 
al., 2016; Plitas et al., 2016).  
 
Given the relevance of target molecule density to the activity of immune 
modulatory antibodies in mouse models (Bulliard et al., 2013, 2014; Selby et 
al., 2013; Simpson et al., 2013), the relative expression of CTLA-4 on 
circulating and tumour-infiltrating CD4+FoxP3+, CD4+FoxP3- and CD8+ T 
lymphocytes was evaluated via multi-parametric flow cytometry. Preliminary 
analysis of human melanoma demonstrated an expression profile consistent 
with mouse models (Figure 5) 
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Figure 5: Preliminary analysis of CTLA-4 expression in human melanoma  
Intracellular (i) CTLA-4 expression was evaluated on (A) circulating and (B) tumour-infiltrating 
CD4+FoxP3+, CD4+FoxP3- and CD8+ T cell subsets in patients with advanced melanoma. A 
representative example is displayed in which CTLA-4 is plotted against Ki67. CTLA-4 
appeared upregulated within the tumour microenvironment and expressed at highest levels 
(based on MFI) in CD4+FoxP3+ Treg. No consistent relationship between Ki67 and CTLA-4 
expression was observed. 
 
Based on these data, analysis of CTLA-4 expression was expanded into 
multiple murine models of transplantable tumour cell lines of variable 
immunogenicity including B16 melanoma, CT26 colorectal carcinoma, 
MCA205 sarcoma, MC38 colonic adenocarcinoma and additional human solid 
tumour subtypes including early-stage NSCLC and varied stage RCC (Figures 
6 and 7).  
 
In mice, CTLA-4 expression was evaluated in tumour-infiltrating lymphocytes 
(TIL), draining lymph nodes (LN) and PBMCs by flow cytometry 10 days after 
tumour challenge. In humans, TILs were isolated from resection specimens 
and PBMCs from peripheral blood sampled at matched time points and 
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evaluated similarly (Chapter 2.3.1 and 2.4.4, Materials and Methods). Across 
all studied mouse models, CTLA-4 expression appeared higher in the tumour 
and was largely restricted to CD4+FoxP3+ Treg cells (mean expression 
68.3%), relative to CD4+FoxP3- effector (CD4+eff) T cells (10.2%, p<0.0001) 
and CD8+ T cells (5.4%, p<0.0001) (Figure 6A-B). Where CTLA-4 expression 
was observed in TIL subsets other than Treg cells, this was at significantly 
lower levels based on mean fluorescent intensity (MFI). Mean MFI of Treg 
cells 2271.8 relative to CD4+eff cells 498.6 (p<0.0001) and CD8+ T cells 701.0 
(p<0.0001) (Figure 6C).   
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Figure 6: CTLA-4 is highly expressed by tumour-infiltrating Treg cells across multiple 
mouse models of cancer. (A) Representative histograms of CTLA-4 expression detected by 
intracellular staining of individual T cell subsets from mice with MCA205 tumours. Grey dotted 
lines represent the gating, numbers indicate percentage of CTLA-4+ cells in each subset.  (B) 
Percentage and (C) MFI of CTLA-4-expressing cells in murine tumour models. Data shown 
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correspond to one of two separate experiments (n=5).  Error bars represent standard error of 
the mean (SEM). 
 
In human tumours, the CTLA-4 expression profile initially observed in 
melanoma appeared consistent across all evaluated tumour subtypes (Figure 
7). Similar to mouse models, higher expression was observed in tumour 
relative to blood and the expression profile amongst individual T cell subsets 
was comparable (mean % CTLA-4+ Treg cells=82.1%, relative to CD4+eff T 
cells=26.5% (p<0.0001) and CD8+ T cells=17.4% (p<0.0001) (Figure 7A-B). 
Although CTLA-4 expression was also observed in a proportion of human 
CD4+eff and CD8+ TILs, this was again at significantly lower levels based on 
MFI (MFI Treg cells=1349.6, relative to CD4+eff T cells=385.9 (p<0.0001) and 
CD8+ T cells=239.4 (p<0.0001) (Figure 7C).  
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Figure 7: CTLA-4 is highly expressed by tumour-infiltrating Treg cells in human 
melanoma, NSCLC and RCC (A) Representative histograms of CTLA-4 expression detected 
by intracellular staining of circulating (PBMC) and tumour-infiltrating (TIL) T cell subsets in a 
patient with advanced melanoma. Grey dotted lines indicate the gating, numbers indicate 
percentage of CTLA-4+ cells in each subset.  (B) Percentage and (C) MFI of CTLA-4 
expression on circulating and tumour-infiltrating T cells in patients with the indicated tumour 
subtypes. Error bars represent standard error of the mean (SEM). 
 
The observed expression profile of CTLA-4 in human tumours raised the 
possibility that anti-human CTLA-4 mAbs might impact on the Treg cell 
compartment in a similar manner to that observed in pre-clinical models. 
However, convincingly demonstrating ADCC or indeed dynamic changes 
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amongst individual T cell subsets within the solid tumour microenvironment 
(relative to blood or bone marrow) is particularly challenging. In attempt to 
overcome this and more effectively mirror the clinical setting, the potential 
utility of a mouse model described to effectively recapitulate human FcγR 
structural and functional diversity was determined through comparison of 
FcγR expression profiles in this model to human melanoma (Smith et al., 
2012). 
 
3.4  FcγR expression in human tumours is recapitulated in a 
transgenic mouse model bearing human FcγRs 
Despite the recognised contributory role of Fc-FcγR interaction to the activity 
of antibody-based therapies, limited data exists regarding FcγR expression in 
human tumours (Furness et al., 2014; Grugan et al., 2012). Translation of 
findings from animal models is complicated by interspecies variation in FcγR 
subtypes, FcγR expression patterns and affinity to IgG subclasses. Moreover, 
therapeutic mAbs are most often evaluated in vitro with use of effector cell 
subsets derived from peripheral blood, on which FcγR expression may not be 
reflective of the tumour microenvironment.  
 
Analysis of human melanoma metastases including subcutaneous, LN and 
colonic resection specimens demonstrated consistent FcγR expression 
profiles on individual cell subsets, but important differences were observed in 
tumour relative to blood (Figure 8).  
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Figure 8: Expression profile of human FcγRs on circulating and tumour-infiltrating cell 
subsets in advanced melanoma 
(A) Representative histograms demonstrating FcγR expression on CD3+CD56- T cells, 
CD19+CD3- B cells, CD56+CD3- NK cells, CD11b+CD14+HLA-DR+ monocytes/macrophages 
(Mono./Mϕ) and CD11b+CD15+CD14- granulocytes isolated from human blood (PBMC) and 
tumour samples. Grey dotted lines indicate gating. (B) Expression profile of FcγRs on 
leukocyte subsets across cohort of studied melanoma lesions (n=10). C) Frequency of 
circulating and tumour-infiltrating cell subsets as percentage of total CD45+ cells and (D) 
expression of individual FcγRs as a percentage of total CD45+ cells. Error bars represent 
SEM. 
 
FcγR expression on lymphocytes in blood and tumour was confined to 
CD19+CD3- B cells, which expressed the inhibitory receptor CD32b. 
Activatory FcγR expression was observed on tumour-infiltrating 
CD11b+CD15+CD14- granulocytes, CD56+CD3- NK cells and 
CD11b+CD14+HLA-DR+ macrophages (MΦ’s). Where NK cells were 
identified, the fraction of CD16a+ cells was consistently lower on tumour-
infiltrating subsets (mean % CD16+ in tumour=41.6% vs. blood=81.1%, 
p<0.05) (Figure 8A and B).  
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Circulating monocytes and tumour-associated MΦ’s expressed all three 
activating FcγRs (CD64, CD32a and CD16a) as well as the inhibitory receptor 
CD32b. Although FcγR distribution remained similar between circulating 
monocytes and tumour-associated MΦ’s, activating FcγRs CD64, CD32a, 
CD16a and the inhibitory FcγR CD32b, were consistently expressed at higher 
levels (based on MFI) on tumour-infiltrating MΦ’s (Figure 8A). Further, CD16a 
and CD32b were consistently expressed by a greater fraction of tumour-
associated MΦ’s than circulating monocytes (mean fraction of CD16+ tumour-
associated MΦ’s=68.1% vs. CD16+ circulating monocytes=15.5% (p <0.05), 
mean fraction CD32b+ tumour-associated MΦ’s=64.7% vs. CD32b+ circulating 
monocytes=4.6% (p<0.05)) (Figure 8B).  
 
In contrast, FcγR expression on circulating and tumour-infiltrating 
granulocytes appeared similar, with constitutive expression of the activatory 
receptors CD32a and CD16b (Figure 8A and B). NK cells and dendritic cells 
(DCs) accounted for a very small fraction of CD45+ tumour-infiltrating cell 
subsets (Figure 8C) (mean % of NK cells=2.26% and DCs=0.95% of total 
CD45+ cells). Dendritic cells were present at too low a frequency for accurate 
profiling of FcγRs. Overall, amongst all tumour-infiltrating leukocyte subsets; 
CD32a was the most abundantly expressed FcγR in human tumours (Figure 
8D). 
 
Analysis of cell subsets in draining LNs, tumour and spleen of hFcγR 
transgenic mice, 10 days after inoculation with MCA205 tumours (Figure 9), 
demonstrated an expression pattern consistent with previous descriptions 
(Smith et al., 2012). Expression of activating FcγRI (CD64), IIa (CD32a) and 
IIIa/b (CD16a/b) was observed on monocytic and granulocytic myeloid cells 
and a small fraction of natural killer (NK) cells (Figure 9A and B). Expression 
of the inhibitory FcγRIIb (CD32b) was observed on B cells and myeloid cell 
subpopulations (Figure 9A and B).  Although this expression pattern was 
maintained on tumour-infiltrating leukocytes, similar to human melanoma, the 
expression levels of all receptors appeared higher in the tumour relative to LN 
or spleen, reflected in a higher MFI, particularly on myeloid cells (Figure 9A). 
Also similar to human tumours, amongst all tumour-infiltrating leukocyte 
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subsets, CD32a appeared the most abundantly expressed FcγR in murine 
tumours (Fig. 9C). 
 
 
Figure 9: Expression profile of human FcγRs in transgenic mice bearing MCA205 
tumours 
(A) Representative histograms demonstrating FcγR expression on CD5+CD19- T cells, CD5-
CD19+ B cells, CD5-NK1.1+ NK cells, CD11b+NK1.1-Ly6G+SSClow monocyte/macrophages 
(Mono./Mϕ) and CD11b+Ly6G+ granulocytes isolated from LN and tumour in hFcγR mice. 
Grey dotted lines indicate gating.  (B) Expression of individual hFcγRs on leukocyte subsets 
in LN, spleen and TILs in hFcγR mice (n=5) and (C) Expression of individual hFcγRs in 
human FcγR mice as a percentage of total live cells. Error bars represent SEM. 
 
Intra-tumoural FcγR expression profiles were largely comparable between 
MCA205 tumours in hFcγR mice and human melanoma. However, expression 
of the inhibitory CD32b in mouse LN and spleen varied relative to blood in 
human melanoma. In the mouse model, in addition to circulating B cells, this 
appeared highly expressed on myeloid cells, whereas in humans expression 
in blood was largely confined to B cells. This could result in a less favourable 
A:I FcγR ratio in secondary lymphoid organs in the mouse model relative to 
	   60	  
human blood and tumours, thus a lack of ADCC activity in these organ sites 
might not necessarily be reflective of the periphery (blood) in humans. 
 
Based on the comparable expression profile of CTLA-4 on T lymphocytes and 
FcγRs on tumour-infiltrating innate effector cell subsets in human melanoma 
and hFcγR mice, the ability of anti-CTLA-4 antibodies of a human isotype to 
promote depletion of intra-tumoural Treg cells in a similar manner to that 
mediated by murine FcγRs was determined (Bulliard et al., 2013; Selby et al., 
2013; Simpson et al., 2013).  
 
3.5  Human IgG1 and IgG2 anti-CTLA-4 antibodies efficiently deplete 
CTLA-4-expressing target cells in vitro  
Chimeric anti-murine CTLA-4 (mCTLA-4) antibodies (based on clone 4F10) 
with the human IgG variants employed in ipilimumab (IgG1) and 
tremelimumab (IgG2) were constructed (performed by Fred Arce-Vargas) and 
their activity compared to mutated IgG1 isotypes with either enhanced binding 
affinity to activatory CD16a (IgG1SDALIE) or no binding to hFcγRs (IgG1N297A).  
 
The capacity of individual mAbs to deplete murine CTLA-4-expressing target 
cells was first assessed in vitro. In attempt to recapitulate the tumour 
microenvironment, monocyte-derived human macrophages with an FcγR 
expression profile reflective of tumour-associated macrophages, were used as 
effector cells at varying effector to target (E:T) cell ratios (Figure 10A). In 
keeping with predicted binding affinity for FcγRs (Figure 10B), IgG1 and IgG2 
mAbs demonstrated superior ADCC activity relative to IgG1N297A . However, 
the IgG1SDALIE mAb promoted enhanced ADCC activity relative to all 
evaluated isoforms at E:T ratios of 2.5:1 and above (Figure 10C). 
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Figure 10: Anti-murine CTLA-4 antibodies of hIgG1 and hIgG2 isotype mediate 
depletion of mCTLA-4-expressing target cells in vitro  (A) FcγR expression on 
CD45+CD14+ subsets in peripheral blood (upper panel) and on the same donor cells following 
7 days of in-vitro differentiation with human recombinant M-CSF (lower panel). (B) Predicted 
ADCC activity of human IgG Fc variants. (C) In-vitro killing of mCTLA-4-expressing target 
cells by human monocyte-derived macrophages at varied effector/target (E:T) ratios, in the 
presence of anti-mCTLA-4 human IgG Fc variants. 
 
3.6 Human IgG1 and IgG2 anti-murine CTLA-4 antibodies efficiently 
deplete intra-tumoural Treg cells in vivo 
The impact of chimeric anti-mCTLA-4 hIgG variants was thereafter 
determined in vivo with use of hFcγR mice. Mice were treated with human 
anti-mCTLA-4 on days 7 and 9 after subcutaneous inoculation with MCA205 
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tumours. On day 11, the frequency of T cell subpopulations was analysed in 
tumour, draining LNs and blood (Figure 11).  
 
 
 
Figure 11: Anti-murine CTLA-4 antibodies of hIgG1 and hIgG2 isotype mediate 
depletion of intra-tumoural Treg cells in vivo  
Mice were treated with 200µg of anti-CTLA-4 mAb on days 6 and 9 after s.c. inoculation with 
MCA205 tumour cells (n=9-21). TILs, LNs and PBMCs were processed on day 11 and 
stained for flow cytometry analysis. (A) Percentage of FoxP3+CD4+ Treg cells of total CD4+ T 
cells in TIL, LN and PBMC compartments and (B) CD8+/Treg cell ratio in the indicated 
anatomical sites.  
 
Consistent with in vitro data, there was a reduction in the proportion of 
tumour-infiltrating Treg cells in mice treated with the IgG1 mAb (mean 
percentage of Treg cells of total CD4+ T cells 24%) compared to those treated 
with the IgG1N297A variant (37%) or to control mice (44%, p<0.001).  The 
depleting activity of the IgG1SDALIE isotype appeared superior to the wild-type 
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IgG1 mAb (mean percentage of Treg cells of total CD4+ T cells 17% vs. 24%, 
respectively), but this did not meet statistical significance. An unexpected 
finding was the observation of efficient IgG2-mediated depletion of tumour-
infiltrating Treg cells in vivo (13% of total CD4+ T cells). The IgG2 isotype is 
often described as a poor mediator of ADCC since it only binds to activatory 
CD32a (Schneider-Merck et al., 2010). However, given the abundance of 
CD32a in the tumour microenvironment, this bears potential relevance to the 
mechanism of action of tremelimumab and other therapeutic human IgG2 
mAbs. 
 
As previously described in wild-type mice (Simpson et al., 2013), the depleting 
activity of all human IgG antibody variants in this new model was restricted to 
the tumour microenvironment, a consequence of the density of target 
molecule expression, with no impact on Treg cells in LNs or blood in hFcγR 
mice (Figure 11A). As a result, anti-CTLA-4 mAb of human IgG1, IgG1SDALIE, 
IgG2 but not IgG1 N297A isotypes, led to a selective increase in the intra-
tumoural ratio of CD8+ to Treg cells (Figure 11B). This was only observed 
within the tumour microenvironment demonstrating that in the context of 
human FcγR-IgG interactions in vivo, depletion of tumour-infiltrating Treg cells 
is a major contributor to the shift in this ratio, which has previously been 
associated with therapeutic responses in mouse and man (Hodi et al., 2008; 
Quezada et al., 2006).  
 
In summary, using a model that allows evaluation of human FcγR-IgG 
interactions in vivo, this data supports a unifying hypothesis in which both of 
the anti-CTLA-4 mAbs employed in the clinic (ipilimumab, IgG1 and 
tremelimumab, IgG2) are likely to promote preferential depletion of tumour-
infiltrating Treg cells and increase the intra-tumoural ratio of Teff to Treg cells. 
Further, these data also suggest that high intra-tumoural expression of CD32b 
may impact on the ADCC activity of human IgG1 anti-CTLA-4 mAbs and this 
may be overcome, at least in part, by engineering of the constant region of the 
antibody to optimise the A:I FcγR binding ratio. 
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3.7 Anti-CTLA-4-mediated intra-tumoural Treg cell depletion underlies 
tumour response and influences long-term survival 
In order to determine the impact of intra-tumoural Treg cell depletion on anti-
tumour activity and survival, hFcγR mice were challenged with subcutaneous 
MCA205 tumours on day 0 and treated with 50µg of chimeric anti-mCTLA-4 
mAb IgG variants on days 6, 9 and 12 (Figure 12A).  
 
Tumour growth was equivalent in untreated mice and those treated with the 
Fc-silent IgG1N297A anti-mCTLA-4 mAb, demonstrating that CTLA-4 blockade 
alone is insufficient to promote tumour rejection in the context of human FcγR-
IgG interactions (Figure 12B). In contrast, the majority of mice treated with 
either IgG1 or IgG2 anti-CTLA-4 mAb rejected tumours completely (66.67% 
and 80%, respectively). IgG1SDALIE anti-CTLA-4 mAb, with enhanced affinity 
for activating FcγRs, resulted in eradication of established tumours in all 
treated mice, although there was no statistical significance compared to IgG1 
and IgG2 mAbs (Figure 12B). Importantly, responses appeared durable, with 
responding mice from all treatment groups alive for more than 80 days (Figure 
12C).  These data suggest that in a mouse system that models human FcγR-
IgG interactions in vivo, anti-CTLA-4 mAbs with enhanced capacity to deplete 
Treg cells have a favourable impact on tumour response and survival.  
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Figure 12: Anti-CTLA-4-mediated intra-tumoural Treg cell depletion is required for 
tumour response and long term survival  
Human FcγR mice were treated with 50µg of anti-CTLA-4 on days 6, 9 and 12 after s.c. 
inoculation of MCA205 tumour cells.  (A) Diagrammatic representation of the experimental 
protocol. (B) Tumour growth in individual hFcγR mice with each treatment. The tumour 
volume was calculated as the product of three orthogonal diameters. Numbers represent the 
proportion of mice with complete long-term tumour rejection. (C) Kaplan-Meier curve of 
accumulated data from mice in (B) (log rank p<0.0001). Cumulative data of two separate 
experiments for each condition.	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3.8 Human FcγR polymorphisms impact upon response to ipilimumab 
in patients with advanced melanoma 
Determining the relevance of Treg cell depletion to the activity of anti-CTLA-4 
antibodies in the clinical setting has proved challenging. In humans, the 
strongest evidence for a role of FcγR-mediated effector function in tumour-
targeting antibody-based cancer therapies (e.g. Trastuzumab) derives from 
clinical studies demonstrating an association between clinical responses and 
specific alloforms of activating FcγRs inferring higher binding affinity to IgG1, 
particularly the CD16a-V158F and CD32a-H131R single nucleotide 
polymorphisms (SNPs) (Cartron et al., 2002; Musolino et al., 2008; Weng and 
Levy, 2003; Zhang et al., 2007). However, no association between FcγR 
polymorphisms and clinical outcome has yet been described in the context of 
anti-CTLA-4 or other immune checkpoint modulators. 
 
Mutational burden and putative neoantigen burden have been demonstrated 
to influence response to ipilimumab in patients with advanced melanoma 
(Nathanson et al., 2016; Snyder et al., 2014; Van Allen et al., 2015). These 
data point to mutations as a potential substrate for tumour recognition by the 
T cell compartment.  Given the biological relevance of CTLA-4 in the context 
of T cell receptor engagement (Leach et al., 1996), the impact of FcγR 
polymorphism status, obtained from sequencing of germline DNA, on 
response to ipilimumab was determined in the same cohort of patients, with a 
working hypothesis that response would be associated with higher mutational 
or putative neoantigen burden (i.e. a substrate T cell response that could be 
amplified by ipilimumab) and the presence of the CD16a-V158F SNP (since 
ipilimumab is an IgG1 antibody).  
 
In patients with low mutational or low predicted neoantigen burden (defined as 
below the median of the cohort) (Figure 13A and B), neither CD32a-H131R 
nor CD16a-V158F SNPs impacted on outcome. Further, amongst patients 
with high mutational or high predicted neoantigen burden (defined as above 
the median of the cohort), the CD32a-H131 SNP had no additional impact on 
outcome. However, as predicted based on the binding affinity of ipilimumab 
(IgG1) for CD16a, the CD16a-V158F SNP was enriched in patients with high 
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mutational (Figure 13A) or high predicted neoantigen burden (Figure 13B) 
deriving benefit from ipilimumab. Combination of these two metrics appeared 
to better identify long-term responders than considering mutational or 
predicted neoantigen burden alone.  
 
 
 
Figure 13: Human FcγR polymorphisms impact upon response to ipilimumab in 
patients with advanced melanoma 
Overall survival analysis of patients with advanced melanoma treated with ipilimumab with (A) 
low mutational burden (below the median of the cohort) or high mutational burden (above the 
median of the cohort) and (B) low predicted neoantigen burden (below the median of the 
cohort) or high predicted neoantigen burden (above the median of the cohort) with or without 
germline CD32a-H131R or CD16a-V158F polymorphisms.  (Key (lower left) in each plot 
depicts mutational or predicted neoantigen burden and polymorphism status. Log rank p 
values are displayed in individual plots. HR, hazard ratio; CI, confidence interval. 
 
	   68	  
Pembrolizumab is an IgG4 mAb directed against PD-1, with low predicted 
binding affinity to hFcγRs and consequent ADCC activity. In pre-clinical 
studies, anti-PD-1 mAbs were demonstrated to be FcγR independent in vivo, 
the presence of FcγR binding capacity was observed to compromise anti-
tumour activity (Dahan et al., 2015). In attempt to confirm this in human 
dataset, tumour exomes derived from of a cohort of patients with advanced 
non-small cell lung cancer treated with pembrolizumab were analysed (Figure 
14) (Rizvi et al., 2015). 
 
 
 
Figure 14: Human FcγR polymorphisms impact negatively upon response to 
pembrolizumab in patients with advanced NSCLC 
Progression free survival (PFS) analysis of patients with NSCLC treated with pembrolizumab 
with (A) low mutational burden (below the median) or high mutational burden (above the 
median) and (B) low predicted neoantigen burden (below the median) or high predicted 
neoantigen burden (above the median) with or without the germline polymorphisms CD32a-
H131R or CD16a-V158F. Log rank p values are displayed in individual plots. HR, hazard 
ratio; CI, confidence interval. 
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Within this cohort, FcγR polymorphism status was not associated with any 
additional benefit in progression free survival (PFS) in patients with high 
mutational burden (above the median of the cohort) (Figure 14A) or high 
predicted neoantigen burden (above the median of the cohort) (Figure 14B), 
supporting ‘blockade’ as the primary mechanism of activity of this mAb.  
 
However, although overall numbers were small, consistent with pre-clinical 
data and the reported influence of the CD16a-V158F on FcγR binding to IgG4 
(Koene et al., 1997), the presence of high mutational or neoantigen burden 
plus the CD16a-V158F SNP appeared to impact negatively on PFS, relative 
to those with high mutational or neoantigen burden and wild type for CD16, 
although this did not meet significance. 
 
3.9 Discussion and Conclusions 
Pre-clinical studies in mouse models of cancer have demonstrated that the 
activity of certain immune modulatory antibodies may extend beyond receptor 
stimulation or blockade of Teff cells, relying upon concomitant depletion of 
Treg cells for maximal anti-tumour activity (Bulliard et al., 2013, 2014; Selby et 
al., 2013; Simpson et al., 2013).  Preferential depletion of tumour-infiltrating 
Treg cells by antibodies targeting CTLA-4, GITR and OX40 depends upon 
both a higher density of the target molecule on intra-tumoural Treg cells 
compared to Teff cells and the presence of an appropriate population of 
effector cells to mediate ADCC. Despite the growing body of evidence 
supporting the premise that immune modulatory antibodies can bear dual 
(immune modulatory and Treg cell depleting) activity, less evidence exists to 
support that this mechanism of action is as important in the clinical context.  
 
In attempt bridge this translational gap, hFcγR mice and chimeric anti-
mCTLA-4 mAbs with human IgG variants were used to model the rules of 
engagement for human FcγRs and human IgGs in the context of immune 
modulatory mAbs, demonstrating that anti-human CTLA-4 mAbs work, at 
least in part, through depletion of tumour-infiltrating Treg cells. Anti-CTLA-4 
mAbs with the same Fc variants as ipilimumab (IgG1) and tremelimumab 
(IgG2) both induced in vivo depletion of tumour-infiltrating Treg cells in the 
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context of human FcγRs. Antibodies engineered to enhance this activity 
displayed improved anti-tumour activity, whilst those engineered to lack 
ADCC capacity demonstrated poor anti-tumour activity.  The high expression 
of CTLA-4 in tumour-infiltrating Treg cells and the presence of innate effector 
cells expressing high levels of CD16 and CD32a activatory FcγRs both in 
mouse and man likely explain the preferential local depletion in the tumour by 
both antibody isotypes.  
 
These findings are further supported by the demonstration of an association 
between the germline CD16a-V158F polymorphism and improved survival in 
patients with advanced melanoma and high mutational or predicted 
neoantigen burden treated with ipilimumab. The requirement for high 
mutational/neoantigen burden raises the possibility that ADCC activity may 
only be relevant in the context of an inflamed tumour microenvironment. This 
is consistent with previous reports and may explain the modest response 
rates observed in the clinic relative to pre-clinical models (Hodi et al., 2010; Ji 
et al., 2012; Ribas et al., 2013; Robert et al., 2011).  
 
Whilst the extent of the contribution of ADCC to the activity of ipilimumab and 
tremelimumab has not been formally tested, the presented data suggest that it 
is potentially highly relevant, and that further enhancement of ADCC may 
improve anti-tumour activity and survival. Where ADCC activity is desirable, 
the IgG1 isotype is most commonly selected owing to its predicted binding 
affinity for activating FcγRs. However, the intra-tumoural composition of FcγR-
expressing cell subsets is rarely considered, both in terms of the expression 
of individual FcγRs and their relative abundance. In both murine and human 
tumours the activatory FcγR CD16a and the inhibitory receptor CD32b 
appeared upregulated on tumour-associated macrophages relative to LN and 
blood. In keeping with this, IgG1SDALIE mAb, with an optimised A:I 
(CD16:CD32b) binding profile (Lazar et al., 2006), demonstrated superior anti-
tumour activity relative to all evaluated chimeric anti-CTLA-4 Fc variants. 
Although not meeting significance, this is likely to be the result of the 
improved efficacy of intra-tumoural Treg cell depletion observed for IgG1SDALIE 
relative to wild type IgG1. 
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In contrast to the IgG1 isotype, IgG2 is generally regarded as a poor mediator 
of ADCC owing to its relatively low affinity for activatory FcγRs, particularly 
CD16 (Bruhns et al., 2009). However, the Fc effector functions of IgG2 are 
mediated by CD32a, and in vitro data demonstrate that IgG2 mAbs mediate 
effective ADCC via CD32a-expressing mononuclear and PMN cells 
(Schneider-Merck et al., 2010). In further support of these findings, chimeric 
anti-mCTLA-4 IgG2 mAb were observed to deplete intra-tumoural Treg cells 
in vivo with similar efficacy to IgG1 mAb.  These results may be explained by 
the relative abundance of CD32a-expressing tumour-infiltrating myeloid cells, 
observed both in murine tumours and human melanoma samples. Further, the 
binding of IgG2 to inhibitory CD32b is minimal, resulting in a high A:I 
(CD32a:CD32b) ratio that favours Fc effector functions. These results raise 
the possibility that Treg depletion is also involved in the mechanism of action 
of tremelimumab and that polymorphisms might also contribute to its activity, 
since the CD32a-H131R polymorphism confers high binding affinity to IgG2 
(Bruhns et al., 2009; Sanders et al., 1995; Schneider-Merck et al., 2010).  
 
Target molecule density, antibody isotype and the intra-tumoural composition 
of FcγR-expressing cell subsets must all be considered in the design of 
immune modulatory mAbs. Optimal intra-tumoural ADCC activity may depend 
on CD16a or CD32a binding, according to which innate effector cells are 
enriched within the tumour microenvironment. Prospective clinical studies 
should consider exploring the use of polymorphism status and mutational 
burden to better identify those patients likely to respond to immune 
modulatory antibodies armed with dual activity. 
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4 Results 2: CD25 as a selective target for regulatory T cells 
 
4.1 Introduction 
 
Based on the observed determinants of the in vivo activity of anti-CTLA-4 
mAbs, candidate target molecules require comprehensive profiling in order to 
more accurately inform the design of next generation of immune modulatory 
antibodies optimised appropriately for agonistic, blocking or depleting activity. 
Mapping the expression of co-inhibitory and co-stimulatory molecules formed 
an initial second objective of this thesis. However, whilst this identified a 
number of additional target molecules suitable for immune modulation, these 
data also highlighted significant overlap in the expression of target molecules 
between T lymphocyte subsets, prompting a search for more selective targets 
restricted to individual T cell subsets.  Flow-based screening of candidate 
molecules identified CD25 as a more restricted target to Treg cells and 
prompted further evaluation of the in vivo activity of anti-CD25 mAbs in mouse 
models of cancer and validation of CD25 as a therapeutic target in human 
cancers.  
 
Specific objectives were to: 
 
(i) Map the expression of co-inhibitory and co-stimulatory immune 
checkpoint molecules in mouse models and human cancers 
 
(ii) Re-evaluate CD25 as a selective target for Treg cells  
 
(iii) Determine the in vivo activity of anti-CD25 mAbs  
 
(iv) Validate CD25 as a therapeutic target in human cancers 
 
In vivo mouse work was performed by Fred Arce Vargas. Ex vivo work was 
performed together with Andrew Furness. Study of human samples was 
performed independently by Andrew Furness. Surface plasmon resonance 
analyses were performed by the Ravetch laboratory. 
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4.2 Distinct expression profiles of co-inhibitory and co-stimulatory 
immune checkpoint molecules in mouse models and human 
cancers 
 
Beyond CTLA-4 and PD-1, multiple co-inhibitory and co-stimulatory immune 
checkpoint molecules are expressed on TILs and represent potential targets 
for immune modulation with antibody-based therapies. Flow cytometry 
analysis of single cell suspensions generated from murine (subcutaneous 
B16, CT26, MCA205 and MC38) and human (melanoma, NSCLC and RCC) 
tumours demonstrated significant heterogeneity in expression profiles 
between tumour subtypes, particularly in molecules typically described on 
effector T cells, including 4-1BB, PD-1 and TIM-3 (Figure 15A). The 
percentage of cells expressing these molecules appeared higher amongst 
CD8+ T cells in the more immunogenic MCA205, MC38 and CT26 mouse 
tumours relative to the poorly immunogenic mouse B16 melanoma and also 
higher in human melanoma relative to NSCLC and RCC, possibly related to 
the immunogenic burden of somatic mutations typically associated with these 
tumour subtypes (Alexandrov et al., 2013). 
 
Despite this, a number of potentially exploitable patterns were observed. 
Similar to CTLA-4, the co-stimulatory receptors GITR, ICOS and OX40 were 
consistently expressed on tumour-infiltrating Treg cells in mouse and human 
tumours. Although expression of these molecules was also observed on 
CD4+FoxP3- and CD8+ T cell subsets, the level of expression, based on MFI, 
was significantly lower than on the Treg cell compartment (Figure 15B). Thus 
GITR, ICOS and OX40 appeared attractive targets in all three human tumour 
subtypes for dual activity antibodies with capacity for ADCC of intra-tumoural 
Treg cells. These findings are consistent with pre-clinical mouse studies, in 
which depleting isotypes of anti-GITR and anti-OX40 demonstrated maximal 
anti-tumour activity in vivo, associated with their ability to enhance effector 
function whilst simultaneously depleting tumour-infiltrating Treg cells (Bulliard 
et al., 2014; Coe et al., 2010). 
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Figure 15: Expression of co-inhibitory and co-stimulatory immune checkpoint 
molecules on tumour-infiltrating T cell subsets in mouse models and human cancers 
(A) Heatmap demonstrating the relative expression of co-inhibitory and co-stimulatory 
molecules quantified by flow cytometry based on the percentage of positive cells within the 
indicated T cell subsets in murine and human tumour subtypes. Data derived from 5 
representative mice and human tumours of each subtype. (B) MFI of the indicated co-
inhibitory and co-stimulatory molecules in blood (PBMC) and tumour (TIL) in patients with 
human melanoma, NSCLC and RCC. Error bars represent SEM. 
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4.3 Towards more selective targeting of T cell subsets 
Whilst maximal anti-tumour activity may be achieved through optimisation of 
immune modulatory mAbs displaying dual activity, toxicity is of major concern 
to treating clinicians, particularly as combination strategies are increasingly 
employed (Sharma and Allison, 2015). It therefore becomes equally important 
to develop agents with reproducible, selective activity against individual T cell 
subsets. However, this first requires identification of candidate target 
molecules that consistently display a more restricted expression profile 
amongst T cell subsets.  
 
In order to identify therapeutic targets that might allow more selective 
depletion of Treg cells, the expression profile of molecules previously 
demonstrated to be expressed at high levels on Treg cells, as well as targets 
largely abandoned in the therapeutic setting (e.g. CD25) were re-visited 
(Figure 16).  
 
 
 
Figure 16: Flow-based screening of candidate molecules for selective targeting of Treg 
cells Tumour-infiltrating T cell subsets were analysed by multi-parametric flow cytometry. 
Following identification of live, CD3+CD4+ (upper panel) or CD3+CD8+ (lower panel) subsets, 
FoxP3 (y axis) was plotted against candidate target molecules (x axis) as annotated above 
each plot. A representative example from a primary NSCLC tumour is displayed. Percentages 
are displayed in each quadrant gate. 
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Although CTLA-4, GITR, ICOS and OX40 were expressed at high levels 
(based on MFI) on tumour-infiltrating CD4+FoxP3+ Treg cells, a significant 
fraction of CD4+FoxP3- effectors and to a lesser extent CD8+ T cells also 
expressed these molecules. The concern in this context is not potential 
elimination of CD4+FoxP3- or CD8+ cell subsets expressing relevant target 
molecules, since preferential depletion of only the highest expressers has 
been demonstrated in vivo (Simpson et al., 2013). Rather, that mAb-induced 
enhancement of effector function might precipitate off target toxicity. In 
contrast, CD25 expression was observed to be largely restricted to 
CD4+FoxP3+ Treg cells on which it was expressed at highest levels. CD25 
therefore appeared a promising therapeutic target to take forward for more 
comprehensive evaluation.  
 
4.4 CD25 expression profiles in mouse models and human cancers 
validate its use as a target for therapeutic Treg cell depletion 
To validate the potential translational value of CD25 as a selective target for 
Treg cell depletion, the expression of CD25 on PBMCs and TILs in a larger 
cohort of patients with advanced melanoma, early-stage NSCLC and RCC 
was evaluated by flow cytometry (Figure 17).  
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Figure 17: CD25 expression is largely restricted to Treg cells in human tumours (A) 
Histograms demonstrating relative expression of CD25 on CD8+, CD4+FoxP3- and 
CD4+FoxP3+ cell subsets in blood and tumour. A representative example of NSCLC is 
displayed. Grey dotted lines indicate gating. (B) Percentage expression of CD25 on CD8+, 
CD4+FoxP3- and CD4+FoxP3+ cell subsets in blood (PBMC) and tumour in patents with 
advanced melanoma (n=8), NSCLC (n=8) and RCC (n=8). (C) MFI of CD25 expression on 
individual cell subsets in blood and tumour within the same cohort. Error bars represent SEM. 
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CD25 expression appeared largely restricted to CD4+FoxP3+ Treg cells (mean 
% CD25+=54.8% of CD4+FoxP3+, 7.5% of CD4+FoxP3- and 1.9% of CD8+; 
p<0.0001) (Figure 17A and B). Further, the level of CD25 expression, as 
assessed by MFI, was significantly higher on CD4+FoxP3+ Treg cells relative 
to CD4+FoxP3- and CD8+ T cells within all studied tumour subtypes (mean 
MFI CD4+FoxP3+=190.0, CD4+FoxP3-=34.5 and CD8+=17.9; p<0.0001) 
(Figure 17C). These findings were remarkably consistent, despite potential 
variability in immunogenicity of individual tumours and significant 
heterogeneity in the clinical characteristics of the studied patient population 
(Chapter 2.4.3.1, Materials and Methods) and were further supported by data 
derived from multiple models of transplantable tumour cell lines of variable 
immunogenicity including MCA205 sarcoma, MC38 colon adenocarcinoma, 
B16 melanoma and CT26 colorectal carcinoma (Figure 18).  
 
Consistently, in multiple mouse models of cancer, in contrast to reports from 
in vitro studies (reviewed in Boyman and Sprent, 2012), minimal expression of 
CD25 on the Teff cell compartment (CD4+FoxP3-  and CD8+ subsets) was 
observed in vivo and the percentage of CD25-expressing Teff cells 
(CD8+=3.08-8.35%, CD4+FoxP3-=14.11-26.87%) was significantly lower than 
on Treg cells (83.66-90.23%) (p<0.001) (Figure 18A and B). CD25 expression 
was also observed on Treg cells present in draining lymph nodes and blood. 
However, the level of expression, based on mean fluorescence intensity (MFI) 
was significantly lower than that observed on tumour-infiltrating Treg cells 
(Figure 18C).  
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Figure 18: CD25 expression is largely restricted to tumour-infiltrating Treg cells in 
mouse models of cancer 
(A-C) Mice were injected subcutaneously (s.c.) in the flank with MCA205 (5x105 cells, 
C57BL/6 mice, n=10), MC38 (5x105 cells, C57BL/6 mice, n=5), B16 (2.5x105 cells, C7BL/6 
mice (n=3) or CT26 (5x105 cells, BALB/c mice, n=3) cells. LNs and TILs were processed 10 
days after tumour challenge and analysed by flow cytometry. (A) Representative histograms 
demonstrating expression of CD25 on T cell subsets in LNs and TILs. Dotted lines represent 
gating of CD25+ cells.  (B) Percentage and (C) MFI of CD25 in each T cell subpopulation. 
Error bars represent standard error of the mean (SEM). The experiment was repeated three 
times. 
 
	   80	  
Taken together these data suggested that CD25 is a largely selective target 
for Treg cells in mouse models and human cancers and that the lack of anti-
tumour activity observed in pre-clinical mouse models is unlikely to relate to 
depletion of CD25-expressing effector T cell populations. Further in vivo study 
was therefore required to decipher the activity of the most extensively studied 
anti-CD25 mAb (clone PC61, rat IgG1, λ), here labelled αCD25-r1, which had 
previously displayed limited activity against established tumours in pre-clinical 
studies (Golgher et al., 2002; Jones et al., 2002; Onizuka et al., 1999; 
Quezada et al., 2008; Shimizu et al., 1999). 
 
4.5 Anti-CD25-r1-mediated depletion of Treg cells is confined to 
lymph node and blood  
 
Consistent with existing pre-clinical data (Onizuka et al., 1999; Setiady et al., 
2010), administration of 200µg of αCD25-r1 on day 5 after tumour challenge 
resulted in a reduced frequency of CD25+FoxP3+ cells (detected with an anti-
CD25 antibody binding to a different epitope to the therapeutic mAb) in 
PBMCs and LN. However, αCD25-r1 failed to deplete tumour-infiltrating Treg 
cells, which demonstrated a CD4+FoxP3+, but CD25- phenotype following 
therapy (Figure 19A and B). Their frequency remained comparable to that of 
untreated mice, potentially explaining the lack of efficacy observed against 
established tumours in previous studies, despite an apparent reduction in 
CD25+ T cells within the tumour (Golgher et al., 2002; Jones et al., 2002; 
Onizuka et al., 1999; Quezada et al., 2008; Shimizu et al., 1999).  
 
Previous analysis of the tumour microenvironment in mouse models and 
human melanoma metastases highlighted the importance of activatory and 
inhibitory FcγRs in influencing the ADCC activity of therapeutic mAbs. In both 
mouse and human tumours, upregulation of the inhibitory FcγR CD32b was 
observed. In acknowledgement of this as a potential explanation for the lack 
of intra-tumoural ADCC activity observed with αCD25-r1, the impact of an 
anti-CD25 mAb optimised for ADCC activity was determined. The constant 
region of the original anti-CD25 mAb obtained from clone PC61 was replaced 
with murine IgG2a and κ constant regions (αCD25-m2a) (performed by Fred 
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Arce Vargas), the classical mouse isotype associated with ADCC. Thereafter, 
its in vivo activity was compared to both αCD25-r1 and, as a control, the anti-
CTLA-4 mAb (clone 9H10), previously described mediate effective depletion 
of intra-tumoural Treg (Simpson et al., 2013). 
 
Both anti-CD25 antibody variants resulted in reduced expression of CD25 on 
T cells and a reduction in the number of Treg cells in blood and LN, but only 
αCD25-m2a resulted in depletion of tumour-infiltrating Treg cells to levels 
comparable to those observed with anti-CTLA-4 mAb. The observed loss of 
CD25 expression with the PC61 variant likely related to downregulation of the 
receptor or mAb-induced capping (Figure 19A and B). In keeping with these 
observations, both anti-CD25 isotypes resulted in an increased Teff/Treg cell 
ratio in blood and LN, but only αCD25-m2a increased the intra-tumoural ratio 
in a similar manner to anti-CTLA-4 (Figure 19C).  
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Figure 19: Anti-CD25-r1 fails to deplete tumour-infiltrating Treg cells 
Tumour-bearing mice were injected with 200µg of anti-CD25-r1 (αCD25-r1), anti-CD25-m2a 
(αCD25-m2a) or anti-CTLA-4 (αCTLA-4) on days 5 and 7 after s.c. inoculation with 5x105 
MCA205 cells. Peripheral blood mononuclear cells (PBMC), lymph nodes (LN) and tumours 
(TIL) were harvested on day 9, processed and stained for flow cytometry analysis. (A) 
Expression of CD25 (detected with antibody clone 7D4) and FoxP3 on CD4+ T cells. (B) 
Percentage of FoxP3+ cells from total CD4+ T cells. (C) CD8+/Treg ratios in PBMC, LN and 
TIL.  
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In contrast to CTLA-4, CD25 is expressed at high levels in blood and tumour. 
However, ADCC of Treg cells with αCD25-r1 was only observed in PBMC and 
LN suggesting a tumour-specific mechanism of inhibition. This did not appear 
to relate to a lack of intra-tumoural T cell infiltration which had been identified 
previously (Quezada et al., 2008). Based on previous observations, the 
expression of activatory and inhibitory FcγRs on individual leukocyte 
subpopulations in the blood, spleen, LN and tumour was determined. Further, 
the binding affinity of the two anti-CD25 Fc variants to activatory and inhibitory 
FcγRs was evaluated in attempt to shed light on the dissociation in activity of 
αCD25-r1 mAb observed between blood, LN and tumour. 
 
4.6 Fc gamma receptor IIb and variable A:I binding profiles influence 
the depleting activity of anti-CD25 antibodies 
 
Expression of activatory and inhibitory FcγRs appeared higher on tumour-
infiltrating myeloid cells (granulocytic cells, dendritic cells and 
monocyte/macrophages) relative to all other studied organs (Figure 20A).  
Given the impact of antibody isotype in determining affinity for FcγRs, the 
binding affinity of the two Fc variants of anti-CD25 to FcγRs was evaluated by 
surface plasmon resonance (SPR) (performed by the Ravetch laboratory) 
(Figure 20B). Consistent with previous descriptions (Nimmerjahn and 
Ravetch, 2005), the mIgG2a isoform was observed to bind to all FcγR 
subtypes with a high activatory to inhibitory ratio. In contrast, αCD25-r1 (rat 
IgG1) was observed to bind to only a single activatory FcγR, FcγRIII, as well 
as the inhibitory FcγRIIb. However, in contrast to the mIgG2a isoform, the 
binding affinity to FcγRIII and FcγRIIb appeared similar, resulting in a low A/I 
ratio (<1) (Figure 20B).  
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Figure 20: Intra-tumoural Fc gamma receptor expression and binding affinity of anti-
CD25 Fc variants (A-B) Expression of FcγRs was assessed by flow cytometry in blood, 
spleen, LN and s.c. MCA205 tumours (TIL) 10 days after tumour challenge. (A) 
Representative histograms demonstrating expression of FcγRs on granulocytes (CD11b+ 
Ly6G+), conventional dendritic cells (cDC)  (CD11chigh MHC-II+) and monocyte/macrophages 
(Mono/Mϕ) (CD11b+ Ly6G- NK1.1- CD11clow/neg). Grey dotted lines indicate gating. (B) The 
binding affinity of rat IgG1 and mouse IgG2a isotypes to murine FcγRs as determined by 
surface plasmon resonance. 
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In order to determine which specific FcγRs were involved in anti-CD25-
mediated Treg cell depletion, the number of tumour-infiltrating Treg cells in 
mice lacking expression of individual FcγRs was evaluated (Figure 21).  
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Figure 21: FcγRIIb inhibits αCD25-r1-mediated Treg cell depletion in tumours 
(A-D) Wild-type (wt), Fcer1g-/-, Fcgr3-/-, Fcgr4-/- or Fcgr2b-/- mice were injected with 5x105 
MCA205 cells s.c. and treated with 200µg of αCD25 Fc variants on days 5 and 7. Tissues 
were harvested and processed for flow cytometry analysis on day 9. Treg (CD4+FoxP3+) as a 
percentage of total tumour-infiltrating CD4+ T cells is displayed. 
 
Analysis of Fcer1g-/- mice, which lack expression of activating FcγRs (I, III and 
IV), demonstrated a complete absence of Treg cell depletion. These data 
confirmed that Treg cell elimination by αCD25-r1 in the periphery, and Treg 
cell elimination by αCD25-m2a in the periphery and tumour, is mediated by 
FcγR-dependent ADCC and is not the result of blocking IL-2 binding to CD25 
(Figure 21A). Intra-tumoural Treg cell depletion by αCD25-m2a was not 
dependent on any individual activatory FcγR, with Treg cell elimination 
observed in both Fcgr3-/- and Fcgr4-/- mice (Figure 21B and C). However, 
critically, in mice lacking expression of the inhibitory receptor FcγRIIb, intra-
tumoural Treg cell depletion by αCD25-r1 was effectively restored and 
comparable between αCD25-r1 and αCD25-m2a (Figure 21D). The lack of 
Treg cell depletion by αCD25-r1 in the tumour is therefore explained by its low 
A/I binding ratio and high intra-tumoural expression of FcγRIIb.  
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In order to cement the translational value of these findings and demonstrate a 
context in which anti-CD25 mAbs may have therapeutic value, longitudinal 
assessment of CD25 expression on TIL subsets was evaluated in patients 
undergoing immune checkpoint modulation. The particular relevance of this 
was to ensure, similar to pre-clinical findings, that CD25 expression remains 
restricted to Treg cells, even in the context of an inflamed human tumour 
microenvironment. 
 
4.7 CD25 expression remains consistent on TIL subsets in patients 
undergoing immune checkpoint modulation 
Core biopsies were performed on the same tumour lesion at baseline and 
following 4 cycles of either nivolumab (3mg/kg Q2W) or 2 cycles of 
pembrolizumab (200mg Q3W) in patients with advanced kidney cancer and 
melanoma respectively (Figure 22). Despite systemic immune modulation, 
CD25 expression remained restricted to FoxP3+ Treg cells, even in areas of 
dense CD8+ T cell infiltrate evaluated by multiplex IHC (Figure 22A and 
quantified in Figure 22B). These findings confirmed the translational value of 
the described pre-clinical data and lend further support to the concept of 
selective therapeutic targeting of Treg cells via CD25 in human cancers. 
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Figure 22: CD25 expression on TIL subsets in patients undergoing PD-1 blockade  
(A) Longitudinal analysis of CD25 expression in human melanoma (n=4) and RCC (n=2) 
lesions prior to (‘Baseline’) and during PD-1 blockade (‘On therapy’). CD8 staining is 
displayed in red, FoxP3 in blue and CD25 in brown. (B) Quantification of CD25 expression 
(%) of tumour-infiltrating CD8+ and FoxP3+ T cells at baseline and during PD-1 blockade. 
Plotted values derive from analysis of 10 x40 high power fields (HPF) per patient at each 
sampling time point. 
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4.8 Discussion and Conclusions 
CD25 appeared an attractive target for Treg cell depletion owing to its 
restricted expression profile in both mouse models and human cancers. 
Contrary to in vitro studies, minimal expression of CD25 was observed on 
effector T cells in vivo in mouse models or in human subjects undergoing 
immune checkpoint blockade.  
 
The efficacy of anti-CD25 as an anti-tumour therapy appears to depend upon 
effective Treg cell depletion in the tumour microenvironment, which can only 
be achieved by using an antibody isotype optimised for engagement of 
activating FcγRs. These data suggest that the limited activity observed in pre-
clinical studies evaluating the anti-CD25 PC61 mAb is likely explained 
ineffective or suboptimal intra-tumoural Treg cell depletion, a consequence of 
its low A:I binding ratio and high intra-tumoural expression of inhibitory 
FcγRIIb.  
 
High intra-tumoural expression of CD32b might also explain the modest 
results observed in early clinical trials of the anti-human CD25 antibody 
daclizumab. However, the impact of anti-human CD25 antibodies of varied 
IgG subclass remains to be evaluated and further, data presented above in 
the context of patients treated with anti-human CTLA-4 mAbs, suggest that 
Treg cell depletion strategies may only be relevant in the context of T cell 
inflamed tumours. 
 
Treg cell depletion may be achieved by targeting other highly expressed 
molecules such as CTLA-4, GITR and OX40 (Bulliard et al., 2013, 2014; Coe 
et al., 2010; Selby et al., 2013; Simpson et al., 2013). However, in contrast to 
CD25, these molecules are simultaneously expressed by Teff cells. Although 
immune modulatory mAbs armed with dual activity may display enhanced 
activity as monotherapy, a concern is that simultaneous expansion of the 
effector cell compartment could precipitate off target toxicity, particularly when 
used in combination. Anti-CD25 mAbs lack the additional cell-intrinsic immune 
modulatory activity of anti-CTLA-4 antibodies and may therefore be more 
attractive as a candidate combination partner in clinical trials. 
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5 Results 3: Neoantigen heterogeneity shapes anti-tumour 
immunity 
 
5.1 Introduction 
 
The majority of current immunotherapeutic approaches are only relevant in 
the context of tumours with an abundant T cell infiltrate. Paucity of immune 
infiltration is not uncommon and well recognised amongst those studying the 
immune tumour microenvironment of human tumours, although rarely 
acknowledged in the literature (Melero et al., 2014). It follows that identifying 
underlying drivers of T cell infiltration or indeed methods of promoting T cell 
infiltration is an area of high scientific priority. 
 
Tumour-specific mutations have recently been recognised to serve as 
neoantigens, eliciting T cell reactivity and impacting on survival (Brown et al., 
2014) and response to immune checkpoint blockade (Rizvi et al., 2015; 
Snyder et al., 2014; Van Allen et al., 2015). Whilst circulating T cells have 
been demonstrated to recognise tumour-specific neoantigens in vitro (Rizvi et 
al., 2015; Snyder et al., 2014), tumour-infiltrating neoantigen-reactive T cells 
(NARTs) and the pathways acting to regulate their activity are poorly 
described. The final objective of this study was to identify and characterise 
these subsets in primary NSCLC, a tumour subtype recognised to harbour a 
high burden of somatic mutations and therefore potential neoantigens 
(Alexandrov et al., 2013; Schumacher and Schreiber, 2015) 
 
Bioinformatics analyses were performed by Nicholas McGranahan and 
Rachel Rosenthal and interpreted together with Andrew Furness. 
Immunological analysis of human samples was performed independently by 
Andrew Furness and in collaboration with the Hadrup laboratory. 
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5.2 Clonal architecture of somatic mutations in primary NSCLC 
Initial analyses focused on two patients, L011 and L012. Multi-regional 
sampling of primary tumours was performed, isolating matched tumour 
regions for paired genomic and immunological analyses. Individual tumour 
regions were subjected to whole exome sequencing (WES) and identified 
somatic mutations plotted as phylogenetic trees (Figure 23). Intra-tumour 
heteroegeneity in primary NSCLC is well described (de Bruin et al., 2014; 
Jamal-Hanjani et al., 2017). In keeping with this, despite a comparable 
smoking history, the clonal architecture of somatic mutations in L011 and 
L012 varied considerably, with L011 displaying a relatively small subclonal 
fraction (4%) relative to L012 (44%).  
 
Figure 23: Clonal evolution of primary NSCLC  
Phylogenetic trees depict clonal and subclonal mutations for patient L011 (left) and L012 
(right). Somatic alterations shared by all tumour cells (clonal) occur early in tumourigenesis 
(blue trunk). Alterations shared by tumour cells present some regions of the tumour but not all 
(shared subclonal) occur later in tumourigenesis (yellow branches) and alterations present in 
only one region of the tumour (private subclonal) also occur later in tumourigenesis (red 
branches). Additional patient demographics and tumour characteristics are displayed below 
including tumour subtype, where LUAD = lung adenocarcinoma, LUSC = lung squamous cell 
carcinoma, GL = germ line and R = region. 
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5.3 In-silico prediction of putative neoantigens 
With use of an established bioinformatics pipeline, putative neoantigens were 
shortlisted based on predicted binding affinity (<500nM) to the patient’s 
human leucocyte antigen (HLA) (performed by McGranahan and Rosenthal). 
A total of 313 neoantigens were predicted from the mutations within the 
primary tumour of L011, 88% of which were clonal, identified in every region 
of the primary tumour. Conversely, L012, a squamous cell carcinoma, 
exhibited a relatively low mutational burden and extensive intra-tumoural 
heterogeneity (ITH), with 75% of the predicted neoantigens deriving from 
subclonal mutations, present only in a subset of cancer cells. 
 
Mutant peptides were synthesised in vitro, based on the sequence of putative 
neoantigens (outsourced to Pepscan, Chapter 2.6, Materials and Methods). 
Simultaneously, tumour-infiltrating lymphocytes from individual tumour regions 
were expanded to large numbers in vitro. With use of fluorescent-labelled 
MHC (major histocompatibility complex) multimers bearing putative 
neoantigens, TILs were screened for reactivity in vitro (Figure 24). 288 and 
354 putative neoantigen-loaded MHC multimers were first used to screen in 
vitro expanded CD8+ T cells derived from individual tumour and normal tissue 
regions from patients L011 and L012 respectively, using a previously 
described high-throughput method (Figure 24A-D) (Hadrup et al., 2009).  
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Figure 24: High-throughput screening of in-vitro expanded NSCLC TILs  
(A-B) Screening of expanded, region-specific, tumour-infiltrating CD8+ T lymphocytes and 
control healthy donor (HD) CD8+ PBMCs with MHC multimers bearing candidate neoantigens 
and control HLA-matched viral peptides. The frequency (%) of CD8+ MHC multimer positive 
cells out of total CD3+CD8+ TILs is displayed. (C) Flow plots depicting CD8+ T cell responses 
against MHC multimers bearing mutant MTFR2 in tumour regions (1-3) and adjacent normal 
tissue in patient L011 (D) Flow plots depicting CD8+ T cell responses against MHC multimers 
bearing mutant CHTF18 and mutant MYADM in tumour regions (1-3) and adjacent normal 
tissue in patient L012.  
 
In patient L011, in-vitro expanded tumour-infiltrating CD8+ T cells appeared 
reactive to an HLA-B3501-multimer bearing mutant MFTR2D326Y 
(FAFQEYDSF) (Figure 24A). In L012, two distinct CD8+ T cell populations 
appeared reactive to an HLA-A1101-multimer bearing mutant CHTF18L769V 
(LLDIVAPK) and an HLA-B0702-multimer bearing mutant MYADMR30W 
(SPMIVGSPW) (Figure 24B). Whilst occasional responses against viral 
peptides were observed, confirming the functionality of the employed MHC-
multimer technology, no non-specific reactivity against healthy donor (HD) 
PBMCs was identified. CD8+ T cell responses were identified in all tumour 
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regions (2.8-4.4%) and at a low frequency in adjacent normal lung tissue 
(0.1%) in L011 (Figure 24C). Whilst in L012, responses were detected in all 
tumour regions against mutant CHTF18 and in a single tumour region against 
mutant MYADM (Figure 24D). 
 
High HLA binding affinity (<50nM) was predicted for MFTR2D326Y and 
CHTF18L769V in both wild type and mutant forms (Figure 25A), but only mutant 
peptides were observed to elicit a T cell response. Higher binding affinity to 
mutant (<50nM) versus wild type (>1000nM) peptide was also predicted for 
MYADM (Figure 25B), however reactivity was observed against both. This 
relates to the position of the MYADMR30W peptide in the anchor residue. Here, 
it primarily affects HLA-binding but not T cell recognition. In the absence of 
artificial stabilisation provided in vitro by an MHC multimer system, the low 
predicted affinity of the wild type peptide to HLA would be expected to prevent 
adequate presentation in vivo.  
 
 
Figure 25: Predicted HLA binding affinity to and clonality of identified neoantigens 
(A-B) Putative neoantigens predicted for all missense mutations in L011 and L012. Predicted 
clonal neoantigens are displayed in blue, subclonal in red. MFTR2D326Y, CHTF18L769V and 
MYADMR30W neoantigens are highlighted within relevant plots. (C) Evolutionary trees for L011 
and L012 based on predicted neoantigens. 
 
Analysis of the clonal architecture of confirmed neoantigens demonstrated all 
to be clonal, present on every tumour cell (Figure 25C). This was particularly 
unexpected for L012, given the majority of predicted neoantigens were 
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subclonal. These observations raised the possibility that given their presence 
on every tumour cell, clonal neoantigens may be more effective in eliciting T 
cell responses than subclonal neoantigens.  
 
5.4 Impact of neoantigen clonal architecture on survival in NSCLC 
 
In order to test this hypothesis, a cohort of 106 stage I/II, 43 stage III/IV and 
one unknown stage lung adenocarcinoma (LUAD) case from The Cancer 
Genome Atlas (TCGA) were subjected to neoantigen and clonality analysis 
(Figure 26).  
 
 
 
Figure 26: Impact of neoantigen clonality on overall survival in NSCLC 
(A) Overall survival in TCGA LUAD cohort amongst tumours harbouring high (upper quartile 
of neoantigen burden) versus low (remainder of the cohort) total neoantigen burden (B) high 
(upper quartile of clonal neoantigen burden) versus low (remainder of the cohort) clonal 
neoantigen burden and (C) high (upper quartile of subclonal neoantigen burden) versus low 
(remainder of the cohort) subclonal neoantigen burden. Hazard ratios (HR) and logrank p 
values are displayed within each plot. 
 
In support of the previously described prognostic relevance of tumour 
neoantigens (Brown et al., 2014), a high neoantigen load (defined as the 
upper quartile of the number of neoantigens predicted in the cohort) was 
associated with longer overall survival compared to tumours in the remaining 
quartiles (Figure 26A, p=0.011). However, tumours harbouring a high number 
of predicted clonal neoantigens (defined as the upper quartile of the cohort) 
were associated with significantly improved survival relative to all other 
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tumours in the cohort (Figure 26B, p=0.0077). Conversely, the number of 
predicted subclonal neoantigens was not significantly associated with overall 
survival (Figure 26C, p=0.12). Taken together, these data suggested that 
beyond total neoantigen burden, the clonal status of neoantigens might be 
relevant to immune surveillance/response. 
 
5.5 High clonal neoantigen burden is associated with an inflamed 
tumour microenvironment 
In support of this as a hypothesis, within the same TCGA LUAD cohort, 
differential expression of immune-related genes was evaluated, comparing 
tumours in the upper quartile of clonal neoantigen burden with those in the 
lower three quartiles (Figure 27).  
 
 
Figure 27: Differential expression of immune-related genes in TCGA LUAD cohort 
Heatmap demonstrating differential expression of immune-related genes between TCGA 
LUAD tumours with high and low clonal neoantigen burden, clustered on co-expression. 
Significance values are displayed above and the associated colour key below. Red boxes 
indicate clustering/co-expression. 
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Differential expression of 27 immune-related genes was observed (Figure 27). 
These included CD8A, genes associated with antigen presentation (TAP-1, 
TAP-2), T cell migration (CXCL-10 and CXCL-9), effector T cell function 
(STAT-1, IFN-γ), T cell regulation (PD-1, LAG-3, PD-L1, PD-L2) and cytolytic 
enzymes (granzyme B, H, and A]. All appeared upregulated in tumours with 
high clonal neoantigen burden and were observed to cluster, indicating co-
expression.  
 
These data suggested that high clonal neoantigen burden in LUAD is 
associated with an inflamed tumour microenvironment (IFN-γ, GzmB) 
enriched with activated effector T cells (CD8A), regulated by inhibitory 
immune checkpoint molecules including PD-1, LAG-3 and inhibitory ligands 
PD-L1 and PD-L2. However, these data derived from in-silico analysis alone. 
Earlier in vitro analysis of L011 and L012 had identified expanded, tumour-
infiltrating CD8+ T cells reactive to clonal neoantigens. Since in-vitro 
expansion methods impact upon both phenotypic and functional T cell 
markers, non-expanded, region-specific CD8+ TILS from L011 and L012 were 
screened and characterised in attempt to determine the validity of the 
described immune-related gene expression data. 
 
5.6 Identification of neoantigen-reactive tumour-infiltrating CD8+ T 
cells in primary NSCLC 
MHC multimers bearing mutant MFTR2, CHTF18 and MYADM were used to 
screen lymphocytes isolated directly from tumour regions and normal lung 
tissue of L011 and L012 respectively (Figure 28). These tumour digests had 
not undergone any form of expansion prior to analysis. Individual T cell 
subsets were identified by multi-parametric flow cytometry as described 
previously.  
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Figure 28: MHC multimer analysis of non-expanded tumour-infiltrating CD8+ T cells 
Flow plots demonstrating reactivity to MHC multimers bearing depicted neoantigens in tumour 
regions 1-3 and adjacent normal tissue for (A) L011 and (B) L012. Displayed percentages are 
of total tumour-infiltrating CD8+ T cells. 
 
In L011, CD8+ MTFR2-reactive T cells were reliably identified in all tumour 
regions (R1-R3, 0.79-1.35% of total CD8+ cells) and at very low frequency in 
adjacent normal lung tissue (0.14% of total CD8+ cells). In L012, CHTF18 and 
MYDAM-reactive CD8+ T cell populations were identified in tumour region 2 
where they represented 2.26% and 0.55% of total CD8+ cells respectively. 
Tumour regions 1 and 2 appeared more poorly infiltrated by CD8+ T cells, 
both CHTF18 and MYADM-reactive CD8+ cells were identified, but at much 
lower frequency. Similar to L011, neoantigen-reactive T cells could also be 
identified in adjacent normal lung tissue, but at a lower frequency than in 
tumour regions. 
 
5.7 Characterisation of neoantigen-reactive tumour-infiltrating CD8+ T 
cells in primary NSCLC 
Analysis of immune-related gene expression in the TCGA LUAD cohort 
suggested that primary NSCLC tumours with high clonal neoantigen burden 
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display an inflamed phenotype. Although reactivity of CD8+ T cells towards 
tumour-specific neoantigens has been demonstrated previously (Rizvi et al., 
2015; Snyder et al., 2014), such analyses have only ever incorporated T cells 
derived from peripheral blood; little is known regarding the phenotype of 
tumour-infiltrating CD8+ neoantigen-reactive T cells (NARTs).  
 
Identified tumour-infiltrating CD8+ NARTs reactive to clonal neoantigens in 
L011 and L012, were therefore subjected to multi-parametric flow cytometry 
analysis. Expression of co-inhibitory and co-stimulatory immune checkpoint 
molecules and functional markers was determined and compared to tumour-
infiltrating CD4+ and CD8+NART- T cell subsets (Figure 29). 
 
 
 
Figure 29: Multi-parametric analysis of tumour-infiltrating CD8+ neoantigen-reactive T 
cells 
Following identification of CD3+CD4+, CD3+CD8+NART- and CD3+CD8+NART+ T cell 
populations, relative expression of co-inhibitory (upper panel) and co-stimulatory (lower panel, 
4-1BB and ICOS) immune checkpoint molecules as well as functional markers (lower panel, 
GzmB and Ki67) was evaluated. Grey dotted lines indicate gating. Percentages represent 
fraction of cells within each subset positive for the displayed markers. Representative data is 
displayed for patient L011. 
 
Consistent with previous analyses, CTLA-4 expression was largely restricted 
to the CD4+ T cell compartment, although a small fraction of CD8+NART- 
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(6.95%) and CD8+NART+ (15.7%) cells appeared CTLA-4+. In contrast, PD-1 
was expressed by almost all CD8+NARTs (97.2%) and LAG-3 by a large 
fraction (48.7%), in keeping with the gene expression data derived from the 
TCGA LUAD cohort. TIM-3 was consistently expressed by a modest fraction 
of T cells across all studied subsets (12.3-19.9%), whilst TIGIT was 
expressed by a majority of cells across all studied subsets excluding a small 
fraction of CD4+ T cells (29.9%).  
 
4-1BB has previously been described as a reliable marker of tumour-reactive 
CD8+ T cells (Ye et al., 2014), however interestingly only a small fraction of 
CD8+NARTs appeared 4-1BB+ (7.64%). There are multiple possible 
explanations for this, including the kinetics of 4-1BB upregulation, however 
this will be important to elucidate further in a larger population, as this may 
allow useful differentiation between neoantigen-specific and tumour-
associated antigen-specific T cell subsets. ICOS, another co-stimulatory 
immune checkpoint molecule, displayed a similar expression profile to CTLA-
4, although a larger fraction of CD8+NARTs appeared ICOS+ (36.7%).  
 
Analysis of functional markers demonstrated granzyme B (GzmB) to be 
largely restricted to CD8+ T cell subsets with comparable expression between 
NART- and NART+ subsets. Finally, based on Ki67, the greatest fraction of 
proliferating cells was observed amongst the CD8+NARTs (42.3%) relative to 
CD8+NART- (32.9%) and CD4+ subsets (19.9%).  
 
These data supported the TCGA LUAD gene expression findings, confirming 
PD-1 and LAG-3 as attractive targets for antibody-based blockade and ICOS 
as a target for agonistic mAbs. However, beyond this, given the observed 
prognostic value of clonal neoantigen burden in primary NSCLC and the 
demonstration that CD8+NARTs reactive to clonal neoantigens are almost 
universally PD-1+, the possibility that neoantigen clonal architecture might 
influence sensitivity to PD-1 blockade was raised. 
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5.8 Neoantigen heterogeneity influences sensitivity to PD-1 blockade 
 
Rizvi and colleagues previously demonstrated that mutational and putative 
neoantigen burden influences response to PD-1 blockade in patients with 
advanced NSCLC (Rizvi et al., 2015), however the clonal architecture of 
mutations was not considered in this context. The same dataset was analysed 
with use of the developed bioinformatics pipeline and the clonal architecture 
of putative neoantigens determined (Figure 30A). 
 
A.
B.
 
 
Figure 30: Clonal neoantigen burden and ITH influences response to  
PD-1 blockade  
(A) Samples are grouped according to clinical benefit, with durable clinical benefit on the left 
(green underscore) and no durable benefit on the right (red underscore). Bar plot depicts 
clonal neoantigens in blue and subclonal neoantigens in red. Histological subtype and 
expression of PD-L1 are shown below. (B) Progression-free survival in the same cohort of 
tumours displaying high clonal neoantigen burden (≥70) without an ITH threshold (HR = 0.29 
(0.12−0.69), log rank P=0.0032] or with an ITH threshold of 0.01 (HR=0.20(0.07−0.60), log-
rank P = 0.0017), 0.02 (HR = 0.25 (0.09−0.67), log-rank P=0.0034), or 0.05 (HR = 0.17 
(0.07−0.44), log rank P=0.000061). 
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These data yielded an unexpected finding. Tumours associated with durable 
clinical benefit (DCB, defined as in (Rizvi et al., 2015), partial response or 
stable disease lasting > 6 months) to PD-1 blockade consistently displayed a 
high burden of clonal neoantigens (≥70). However, response to PD-1 
blockade also appeared contingent upon the relative fraction of subclonal 
neoantigens. Almost every tumour (12/13) that exhibited a low neoantigen 
subclonal fraction (<5%) and high neoantigen burden (≥70), demonstrated 
durable clinical benefit with pembrolizumab. In contrast, only 2 out of 18 
tumours with a high subclonal neoantigen fraction (>5%) or low clonal 
neoantigen burden benefited from pembrolizumab. Even in the context of high 
overall putative neoantigen burden, resistance to PD-1 blockade was 
observed in tumours with a high subclonal fraction (e.g. TU0428, ZA6505).  
 
Tumours with both a high clonal neoantigen burden and low neoantigen 
heterogeneity were associated with significantly longer progression free 
survival and this relationship remained robust to the choice of ITH threshold, 
with lower hazard ratios observed compared to using neoantigen burden 
alone (Figure 30B). Further, in keeping the immune-related gene expression 
data and recent clinical data (Reck et al., 2016), strong PD-L1 staining (>50% 
membranous staining) appeared enriched in these patients. 
 
5.9 Discussion and Conclusions 
Neoantigen burden has been demonstrated to influence prognosis (Brown et 
al., 2014) and sensitivity to immune checkpoint blockade in advanced NSCLC 
and melanoma (Rizvi et al., 2015; Snyder et al., 2014; Van Allen et al., 2015). 
However, the impact of ITH in the neoantigen landscape on this relationship 
has not been determined. These data are limited by cohort size and single-
site biopsy data, which can overestimate the fraction of clonal mutations. 
Nevertheless, clonal and subclonal neoantigens do not appear equivalent in 
driving anti-tumour immunity.  
 
The gene expression data derived from the TCGA LUAD cohort are supported 
by protein level findings of NART characterisation. It follows that clonal 
neoantigen burden might be of predictive value in determining response to 
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PD-1 blockade. However, the influence of neoantigen ITH was not 
anticipated. It is curious that despite screening more than 250 peptides 
against putative subclonal neoantigens, only T cells recognising clonal 
neoantigens were detected. Perhaps all can be explained by a unifying 
hypothesis whereby lower antigen dosage secondary to high neoantigen ITH 
is less effective in driving T cell responses with impact on prognosis, response 
to PD-1 blockade and the feasibility of detecting tumour-infiltrating T cells 
reactive to subclonal neoantigens. However, these data should not be over-
interpreted given the number of evaluated patients (n=2) and the possibility 
that other variables, including methods of in-vitro expansion could have 
impacted upon detection of NARTs. 
 
The demonstration that PD-L1 expression appeared enriched in patients with 
high clonal neoantigen burden in TCGA LUAD and Rizvi cohorts is pleasing, 
suggesting this may be a useful surrogate for clonal neoantigen burden and 
neoantigen ITH. NSCLC is the most common cause of cancer death 
worldwide (Cancer Research UK, 2015) and clinically applicable biomarkers 
are much needed, particularly in low- and middle-income countries. Whilst the 
limitations of PD-L1 as a biomarker are recognised given its 
inducible/dynamic nature, it was recently used successfully to stratify NSCLC 
patients to anti-PD-1 therapy versus chemotherapy (Reck et al., 2016).  
 
Perhaps the most important finding amongst these data was also that least 
anticipated. ITH within solid tumours and their metastases is well recognised 
(de Bruin et al., 2014; Gerlinger et al., 2012, 2014; Jamal-Hanjani et al., 2017; 
Jiménez-Sánchez et al., 2017). However, clonal neoantigens represent a 
therapeutic target present on all tumour cells, regardless of subsequent 
evolution. To this end, adoptive cell-based approaches, of particular relevance 
to poorly infiltrated tumours, and/or vaccination strategies, both targeting 
clonal neoantigens, in combination with immune checkpoint modulation may 
hold promise in overcoming the significant challenge posed by ITH. 
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6 Final discussion and conclusions 
 
Dissecting the in vivo activity of anti-CTLA-4 mAbs highlights the importance 
of comprehensively profiling the expression of a candidate target molecule 
and considering the implications of this in the design of a therapy with the 
potential for additional Fc-dependent effector activity. Further, whether in the 
context of malignancy, arthritis, transplant medicine or beyond, these data 
also emphasize the importance of recognising the impact of the local 
microenvironment in determining the activity of a given therapy (Furness et 
al., 2014), a concept perhaps not always considered enough in the pre-clinical 
design of antibody-based therapies.  
 
Within pre-clinical models and human tumours, it will be important to expand 
this work and determine whether innate effector cell infiltration and FcγR 
expression profiles vary across individual tumour subtypes and anatomical 
disease sites. If tissue-resident cell subsets are implicated, this is highly 
plausible. Another important consideration will be the impact of the cytokine 
milieu within the TME on FcγR expression. Tumour-associated macrophages 
are well recognised to display varied activation states within a spectrum of two 
opposing poles: M1 and M2 (Biswas and Mantovani, 2010). These are 
associated with anti- and pro-tumoural activity respectively and are a result of 
the local cytokine milieu; in vitro data suggest cytokines can impact 
significantly upon on FcγR expression on cell lines (Grattage et al., 1992). 
 
Where discrepancy in activity is observed between mouse models and the 
clinic, further investigation, rather than replacement with the next active 
compound is paramount. This is particularly relevant in the setting of immune-
modulatory therapies where the potential benefits for responding patients are 
unparalleled. Anti-CTLA-4 antibodies are an example of this, where the 
impressive activity in mouse models was not recapitulated in the modest 
response rates observed in the clinical setting (Schadendorf et al., 2015). 
However, this is rarely acknowledged, perhaps because ipilimumab was the 
first drug to prolong survival in advanced melanoma (Hodi et al., 2010; Robert 
et al., 2011) and led to the current renaissance of tumour immunotherapy.  
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Having focused efforts on projects evaluating the tumour microenvironment in 
mouse models and human cancers in parallel, it is apparent that a majority of 
models used in this setting (when administered s.c. and excluding B16 
melanoma) are most reflective of an inflamed human tumour 
microenvironment. As such, they are useful for determining the mechanisms 
of immune-based therapies which rely upon an existing inflamed tumour 
microenvironment and potentially also mechanisms of acquired resistance in 
this setting, but are of limited value in understanding intrinsic resistance.  
 
Consistent with this as a potential explanation for the modest response rates 
observed with ipilimumab relative to mouse models (Leach et al., 1996; 
Schadendorf et al., 2015; Simpson et al., 2013), FcγR polymorphisms only 
appear to influence survival in patients with melanoma treated with ipilimumab 
in the context of high mutational or neoantigen burden. When considering the 
clinical development of Treg cell directed strategies, including those targeting 
CD25, this is of potential relevance and stratification may be required to 
identify those most likely to derive benefit. The presented pre-clinical data 
deciphering the in vivo activity of anti-CD25 mAbs also highlight once again 
the importance of considering the microenvironment in which the mAb is 
desired to have activity and potential inhibitory mechanisms that might be 
unique to or enriched within it.  
 
Even in the context of combination immunotherapeutic approaches, a majority 
of patients fail to derive benefit (Gerlinger et al., 2012; Hellmann et al., 2018; 
Melero et al., 2014; Motzer et al., 2018). Paucity of T and NK cell infiltration 
represents a key barrier to the successful clinical application of immune 
checkpoint modulation (Melero et al., 2014). The presented immuno-genomic 
data provides novel insight into underlying drivers of T cell infiltration. A 
number of strategies are in clinical development which aim to promote T cell 
infiltration including oncolytic virotherapies (Ribas et al., 2017), however it 
remains unclear whether promoting T cell infiltration in this manner will 
overcome the challenge posed by intra-tumoural heterogeneity. Debulking 
strategies such as radiotherapy are potentially relevant in this context 
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(Twyman-Saint Victor et al., 2015), although these do not overcome the 
potential requirement for a bottleneck of clonal neoantigens to drive an 
effective immune response. A possible method of overcoming all such 
challenges is the adoptive transfer of T cells reactive to clonal neoantigens, 
however significant challenges are also posed herein including the source of 
T cells, their differentiation status, the ability to successfully infiltrate tumours 
and overcoming the regulatory mechanisms common to any activated T cell.  
 
Recent data suggest that loss of MHC class I expression is not uncommon in 
advanced melanoma, representing an important mechanism of primary 
resistance to checkpoint blockade, but also with implications for adoptive 
therapeutic approaches (Rodig et al., 2018). Despite the focus of this thesis, 
such observations emphasize the importance of looking beyond T cells. 
Myeloid and stromal cells constitute a significant fraction of intra-tumoural cell 
subsets and have capacity to transform the TME (Gentles et al., 2015). 
Indeed, cancer-associated fibroblast-derived transforming growth factor beta 
(TGFβ) was recently demonstrated to play a key role in mediating T cell 
exclusion from tumours, influencing spatial patterns that had been observed 
for many years, yet remained unexplained (Mariathasan et al., 2018) 
 
Within this thesis, the reciprocal exchange of pre-clinical and clinical data has 
been fundamental in driving clinically meaningful discoveries. Wherever 
possible, strategies should be in place for the integration of basic and clinical 
science, in this context collaboration is paramount and the work presented in 
this thesis strives to be reflective of such an approach. 
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